EP3871673A1 - Nouveau composé d'indazole ou sel de celui-ci - Google Patents
Nouveau composé d'indazole ou sel de celui-ci Download PDFInfo
- Publication number
- EP3871673A1 EP3871673A1 EP19874827.9A EP19874827A EP3871673A1 EP 3871673 A1 EP3871673 A1 EP 3871673A1 EP 19874827 A EP19874827 A EP 19874827A EP 3871673 A1 EP3871673 A1 EP 3871673A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- tert
- chloro
- substituted
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 indazole compound Chemical class 0.000 title claims abstract description 278
- 150000003839 salts Chemical class 0.000 title claims abstract description 135
- 150000001875 compounds Chemical class 0.000 claims description 253
- 125000000623 heterocyclic group Chemical group 0.000 claims description 145
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 143
- 125000001424 substituent group Chemical group 0.000 claims description 129
- 229910052736 halogen Inorganic materials 0.000 claims description 115
- 238000004519 manufacturing process Methods 0.000 claims description 111
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 111
- 229910052757 nitrogen Inorganic materials 0.000 claims description 95
- 150000002367 halogens Chemical group 0.000 claims description 84
- 229910052739 hydrogen Inorganic materials 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 79
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 75
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 65
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 64
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 62
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 61
- 229910052799 carbon Inorganic materials 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 51
- 150000001721 carbon Chemical class 0.000 claims description 48
- 150000002829 nitrogen Chemical class 0.000 claims description 45
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 45
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 42
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 42
- 229910052717 sulfur Inorganic materials 0.000 claims description 41
- 239000000460 chlorine Substances 0.000 claims description 39
- 229910052801 chlorine Inorganic materials 0.000 claims description 39
- 239000011593 sulfur Substances 0.000 claims description 39
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 38
- 239000002246 antineoplastic agent Substances 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 27
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 239000001301 oxygen Substances 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 229920002554 vinyl polymer Polymers 0.000 claims description 25
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 24
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 22
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 19
- 229910052805 deuterium Inorganic materials 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 10
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 9
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- IUDHQFWNOROVRT-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-3,5-dimethyl-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC1=C(N(C(=N1)CNC2=NNC3=CC(=C(C=C32)C(C)(C)C)Cl)C)C(=O)NC4CN(C4)C(=O)C=C IUDHQFWNOROVRT-UHFFFAOYSA-N 0.000 claims description 3
- IBWKULOISRIXMQ-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-(difluoromethyl)-3-(1-propan-2-ylpyrrolidin-3-yl)-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)N1CCC(C1)N2C(=NC(=C2C(=O)NC3CN(C3)C(=O)C=C)C(F)F)CNC4=NNC5=CC(=C(C=C54)C(C)(C)C)Cl IBWKULOISRIXMQ-UHFFFAOYSA-N 0.000 claims description 3
- FEYJRULHFIDEST-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-(difluoromethyl)-3-propan-2-yl-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)N1C(=NC(=C1C(=O)NC2CN(C2)C(=O)C=C)C(F)F)CNC3=NNC4=CC(=C(C=C43)C(C)(C)C)Cl FEYJRULHFIDEST-UHFFFAOYSA-N 0.000 claims description 3
- JFUYTUJBCLQYLF-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-(1-methylpiperidin-4-yl)-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C4CCN(CC4)C)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl JFUYTUJBCLQYLF-UHFFFAOYSA-N 0.000 claims description 3
- GCCIWPPELMCZMI-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-(1-propan-2-ylazetidin-3-yl)-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)N1CC(C1)N2C(=NC(=C2C(=O)NC3CN(C3)C(=O)C=C)Cl)CNC4=NNC5=CC(=C(C=C54)C(C)(C)C)Cl GCCIWPPELMCZMI-UHFFFAOYSA-N 0.000 claims description 3
- LAGFOPGFUKKALV-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-(4-methoxycyclohexyl)-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C4CCC(CC4)OC)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl LAGFOPGFUKKALV-UHFFFAOYSA-N 0.000 claims description 3
- KSDNONFALPBINQ-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-(oxan-3-yl)-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C4CCCOC4)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl KSDNONFALPBINQ-UHFFFAOYSA-N 0.000 claims description 3
- FTNHKSSUKYUJEC-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-(oxan-4-yl)-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C4CCOCC4)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl FTNHKSSUKYUJEC-UHFFFAOYSA-N 0.000 claims description 3
- KXWASYCDTBXJSZ-MRXNPFEDSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-[(3R)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3[C@@H]4CCN(C4)CC(F)F)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl KXWASYCDTBXJSZ-MRXNPFEDSA-N 0.000 claims description 3
- DWJDNPUYBQAQEB-GOSISDBHSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-[(3R)-1-propan-2-ylpyrrolidin-3-yl]-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)N1CC[C@H](C1)N2C(=NC(=C2C(=O)NC3CN(C3)C(=O)C=C)Cl)CNC4=NNC5=CC(=C(C=C54)C(C)(C)C)Cl DWJDNPUYBQAQEB-GOSISDBHSA-N 0.000 claims description 3
- SVCLDZLNZSMDKY-OAHLLOKOSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-[(3R)-oxolan-3-yl]-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3[C@@H]4CCOC4)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl SVCLDZLNZSMDKY-OAHLLOKOSA-N 0.000 claims description 3
- JKXRIABVROMSMG-NVXWUHKLSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-[(3R,5R)-1-(2,2-difluoroethyl)-5-methylpyrrolidin-3-yl]-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound C[C@@H]1C[C@H](CN1CC(F)F)N2C(=NC(=C2C(=O)NC3CN(C3)C(=O)C=C)Cl)CNC4=NNC5=CC(=C(C=C54)C(C)(C)C)Cl JKXRIABVROMSMG-NVXWUHKLSA-N 0.000 claims description 3
- KXWASYCDTBXJSZ-INIZCTEOSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-[(3S)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3[C@H]4CCN(C4)CC(F)F)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl KXWASYCDTBXJSZ-INIZCTEOSA-N 0.000 claims description 3
- SVCLDZLNZSMDKY-HNNXBMFYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-[(3S)-oxolan-3-yl]-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3[C@H]4CCOC4)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl SVCLDZLNZSMDKY-HNNXBMFYSA-N 0.000 claims description 3
- NKHHRBCGFXJKAT-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-cyclopentyl-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C4CCCC4)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl NKHHRBCGFXJKAT-UHFFFAOYSA-N 0.000 claims description 3
- SSFDAWGOUVWMKB-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-methyl-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C)C(=O)NC4CN(C4)C(=O)C=C)Cl)Cl SSFDAWGOUVWMKB-UHFFFAOYSA-N 0.000 claims description 3
- ASAFUFALQACICI-ACJLOTCBSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-methyl-N-[(3R,4R)-4-methyl-1-prop-2-enoylpyrrolidin-3-yl]imidazole-4-carboxamide Chemical compound C[C@@H]1CN(C[C@@H]1NC(=O)C2=C(N=C(N2C)CNC3=NNC4=CC(=C(C=C43)C(C)(C)C)Cl)Cl)C(=O)C=C ASAFUFALQACICI-ACJLOTCBSA-N 0.000 claims description 3
- OIWYBKKQVNNNQI-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-propan-2-yl-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC(C)N1C(=NC(=C1C(=O)NC2CN(C2)C(=O)C=C)Cl)CNC3=NNC4=CC(=C(C=C43)C(C)(C)C)Cl OIWYBKKQVNNNQI-UHFFFAOYSA-N 0.000 claims description 3
- IBDKVQXTKKINPB-LJQANCHMSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-N-(1-prop-2-enoylazetidin-3-yl)-3-[(3R)-1-pyridin-2-ylpyrrolidin-3-yl]imidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3[C@@H]4CCN(C4)C5=CC=CC=N5)C(=O)NC6CN(C6)C(=O)C=C)Cl)Cl IBDKVQXTKKINPB-LJQANCHMSA-N 0.000 claims description 3
- LXNPKRACAQWOCI-RDJZCZTQSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-N-[(3S,4S)-4-fluoro-1-prop-2-enoylpyrrolidin-3-yl]-3-methylimidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C)C(=O)N[C@H]4CN(C[C@@H]4F)C(=O)C=C)Cl)Cl LXNPKRACAQWOCI-RDJZCZTQSA-N 0.000 claims description 3
- SRMJRHJSQYLHGC-RDJZCZTQSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-fluoro-N-[(3S,4S)-4-fluoro-1-prop-2-enoylpyrrolidin-3-yl]-3-methylimidazole-4-carboxamide Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C)C(=O)N[C@H]4CN(C[C@@H]4F)C(=O)C=C)F)Cl SRMJRHJSQYLHGC-RDJZCZTQSA-N 0.000 claims description 3
- DEVVVECNCNFWRN-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-methyl-3-propan-2-yl-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CC1=C(N(C(=N1)CNC2=NNC3=CC(=C(C=C32)C(C)(C)C)Cl)C(C)C)C(=O)NC4CN(C4)C(=O)C=C DEVVVECNCNFWRN-UHFFFAOYSA-N 0.000 claims description 3
- XCHLOIYRTYPUEH-HKUYNNGSSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-N-[(3S,4S)-4-fluoro-1-prop-2-enoylpyrrolidin-3-yl]-3,5-dimethylimidazole-4-carboxamide Chemical compound CC1=C(N(C(=N1)CNC2=NNC3=CC(=C(C=C32)C(C)(C)C)Cl)C)C(=O)N[C@H]4CN(C[C@@H]4F)C(=O)C=C XCHLOIYRTYPUEH-HKUYNNGSSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- JBLRAGLNLJHKFF-UHFFFAOYSA-N tert-butyl 3-[2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-4-chloro-5-[(1-prop-2-enoylazetidin-3-yl)carbamoyl]imidazol-1-yl]azetidine-1-carboxylate Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C4CN(C4)C(=O)OC(C)(C)C)C(=O)NC5CN(C5)C(=O)C=C)Cl)Cl JBLRAGLNLJHKFF-UHFFFAOYSA-N 0.000 claims description 3
- 125000004431 deuterium atom Chemical group 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 577
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 279
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 178
- 239000000203 mixture Substances 0.000 description 145
- 239000000243 solution Substances 0.000 description 125
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 120
- 239000012044 organic layer Substances 0.000 description 120
- 238000003756 stirring Methods 0.000 description 120
- 239000002904 solvent Substances 0.000 description 116
- 239000011541 reaction mixture Substances 0.000 description 111
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- 230000002829 reductive effect Effects 0.000 description 96
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 93
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 88
- 238000004440 column chromatography Methods 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 83
- 229910052938 sodium sulfate Inorganic materials 0.000 description 83
- 235000011152 sodium sulphate Nutrition 0.000 description 83
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 81
- 239000007864 aqueous solution Substances 0.000 description 81
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 78
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 78
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 51
- 150000002431 hydrogen Chemical group 0.000 description 46
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 39
- 125000005843 halogen group Chemical group 0.000 description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 238000001816 cooling Methods 0.000 description 35
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 33
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 33
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- 229910052731 fluorine Inorganic materials 0.000 description 28
- 239000011737 fluorine Substances 0.000 description 28
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 25
- 238000000605 extraction Methods 0.000 description 24
- 239000010410 layer Substances 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 23
- 102000016914 ras Proteins Human genes 0.000 description 23
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 22
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 22
- 238000001704 evaporation Methods 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 19
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 18
- 102100030708 GTPase KRas Human genes 0.000 description 17
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 17
- 150000001975 deuterium Chemical group 0.000 description 16
- 125000002950 monocyclic group Chemical group 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- 108010014186 ras Proteins Proteins 0.000 description 15
- 235000017557 sodium bicarbonate Nutrition 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 14
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 14
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 14
- 102200006538 rs121913530 Human genes 0.000 description 14
- 125000006017 1-propenyl group Chemical group 0.000 description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 13
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 12
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 12
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- NFTAFPLJYLZTAU-UHFFFAOYSA-N 5-tert-butyl-6-chloro-1H-indazol-3-amine Chemical compound C(C)(C)(C)C=1C=C2C(=NNC2=CC1Cl)N NFTAFPLJYLZTAU-UHFFFAOYSA-N 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 9
- 125000003386 piperidinyl group Chemical group 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 7
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 7
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 7
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 6
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 6
- 125000002393 azetidinyl group Chemical group 0.000 description 6
- 125000004966 cyanoalkyl group Chemical group 0.000 description 6
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 6
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 6
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 6
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000004423 acyloxy group Chemical group 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 5
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- WPGLRFGDZJSQGI-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C1 WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 5
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 4
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 4
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- PSIXJXSZJOCEFH-UHFFFAOYSA-N 5-bromo-6-chloro-1H-indazol-3-amine hydrochloride Chemical compound Cl.BrC=1C=C2C(=NNC2=CC1Cl)N PSIXJXSZJOCEFH-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- MRUCHHRISLIFRQ-UHFFFAOYSA-N N-(2-bromo-5-tert-butyl-4-chlorophenyl)acetamide Chemical compound BrC1=C(C=C(C(=C1)Cl)C(C)(C)C)NC(C)=O MRUCHHRISLIFRQ-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 238000007112 amidation reaction Methods 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 4
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000012954 diazonium Substances 0.000 description 4
- 150000001989 diazonium salts Chemical class 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- KFYCJKJZRAGHDB-DTWKUNHWSA-N tert-butyl (3S,4S)-3-hydroxy-4-(methylsulfonyloxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]([C@@H](C1)O)COS(=O)(=O)C KFYCJKJZRAGHDB-DTWKUNHWSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- NXAYHNTZDRGKHJ-UHFFFAOYSA-N 2-bromo-5-tert-butyl-4-chlorobenzonitrile Chemical compound BrC1=C(C#N)C=C(C(=C1)Cl)C(C)(C)C NXAYHNTZDRGKHJ-UHFFFAOYSA-N 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000006242 amine protecting group Chemical group 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 description 3
- 125000004069 aziridinyl group Chemical group 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 230000026030 halogenation Effects 0.000 description 3
- 238000005658 halogenation reaction Methods 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- AKDPLDCXQNEMCL-UHFFFAOYSA-N methyl 3-methylimidazole-4-carboxylate Chemical compound COC(=O)C1=CN=CN1C AKDPLDCXQNEMCL-UHFFFAOYSA-N 0.000 description 3
- DESDXDWZSJRLDB-UHFFFAOYSA-N methyl 4-amino-1h-imidazole-5-carboxylate Chemical compound COC(=O)C=1NC=NC=1N DESDXDWZSJRLDB-UHFFFAOYSA-N 0.000 description 3
- KJPUFJGIXOLOQC-UHFFFAOYSA-N methyl 5-chloro-1h-imidazole-4-carboxylate Chemical compound COC(=O)C=1NC=NC=1Cl KJPUFJGIXOLOQC-UHFFFAOYSA-N 0.000 description 3
- AYOKWZVUNXLHJR-UHFFFAOYSA-N methyl 5-chloro-3-methylimidazole-4-carboxylate Chemical compound N1(C)C=NC(=C1C(=O)OC)Cl AYOKWZVUNXLHJR-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012285 osmium tetroxide Substances 0.000 description 3
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- MQQXLNIOWUAKJW-UHFFFAOYSA-N tert-butyl 3-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-6-chloro-5-(3,3,3-trifluoroprop-1-en-2-yl)indazole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C2=CC(=C(C=C2C(=N1)N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(=C)C(F)(F)F)Cl MQQXLNIOWUAKJW-UHFFFAOYSA-N 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- BXPDWDKVELRCJH-UHFFFAOYSA-N 1-(3-aminoazetidin-1-yl)prop-2-en-1-one hydrochloride Chemical compound C=CC(=O)N1CC(C1)N.Cl BXPDWDKVELRCJH-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- IPFOCHMOYUMURK-UHFFFAOYSA-N 1-[3-[4-[2-[4-chloro-2-hydroxy-5-(1-methylcyclopropyl)anilino]acetyl]piperazin-1-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C=1C(NCC(=O)N2CCN(CC2)C2CN(C2)C(=O)C=C)=C(O)C=C(Cl)C=1C1(C)CC1 IPFOCHMOYUMURK-UHFFFAOYSA-N 0.000 description 2
- XACFLGSMDUITKB-UHFFFAOYSA-N 1-bromo-4-tert-butyl-2-nitrobenzene Chemical compound CC(C)(C)C1=CC=C(Br)C([N+]([O-])=O)=C1 XACFLGSMDUITKB-UHFFFAOYSA-N 0.000 description 2
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 2
- XKQHHUHQLZZEBW-UHFFFAOYSA-N 1-methyl-4-(trifluoromethyl)imidazole-2-carbaldehyde Chemical compound CN1C=C(C(F)(F)F)N=C1C=O XKQHHUHQLZZEBW-UHFFFAOYSA-N 0.000 description 2
- HNALLRIDASDXQI-UHFFFAOYSA-N 2-(2-benzhydrylidenehydrazinyl)-5-tert-butyl-4-chlorobenzonitrile Chemical compound CC(C)(C)C1=C(C=C(C(=C1)C#N)NN=C(C2=CC=CC=C2)C3=CC=CC=C3)Cl HNALLRIDASDXQI-UHFFFAOYSA-N 0.000 description 2
- JFLFUVYTSZLXLT-UHFFFAOYSA-N 2-(diethoxymethyl)-1-methyl-4-(trifluoromethyl)imidazole Chemical compound C(C)OC(C=1N(C=C(N1)C(F)(F)F)C)OCC JFLFUVYTSZLXLT-UHFFFAOYSA-N 0.000 description 2
- MEBFFOKESLAUSJ-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyacetaldehyde Chemical compound CC(C)(C)[Si](C)(C)OCC=O MEBFFOKESLAUSJ-UHFFFAOYSA-N 0.000 description 2
- HEQYQRXVNCGODT-UHFFFAOYSA-N 2-bromo-4-chloro-5-propan-2-ylbenzonitrile Chemical compound CC(C)C1=C(C=C(C(=C1)C#N)Br)Cl HEQYQRXVNCGODT-UHFFFAOYSA-N 0.000 description 2
- AGGLSLMALQJLSZ-UHFFFAOYSA-N 2-bromo-5-tert-butyl-4-chloroaniline Chemical compound BrC1=C(N)C=C(C(=C1)Cl)C(C)(C)C AGGLSLMALQJLSZ-UHFFFAOYSA-N 0.000 description 2
- JUDMIHUYBBEFCG-UHFFFAOYSA-N 2-bromo-6-tert-butyl-3,5-dichloropyridine Chemical compound CC(C)(C)C1=NC(=C(C=C1Cl)Cl)Br JUDMIHUYBBEFCG-UHFFFAOYSA-N 0.000 description 2
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 2
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- OPSKQGQJCODPET-UHFFFAOYSA-N 3,5-dimethylimidazole-4-carboxylic acid Chemical compound CC=1N=CN(C)C=1C(O)=O OPSKQGQJCODPET-UHFFFAOYSA-N 0.000 description 2
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 description 2
- MWXDWVWIRFDRAC-UHFFFAOYSA-N 5-bromo-2-(diethoxymethyl)-1-methyl-4-(trifluoromethyl)imidazole Chemical compound CCOC(C1=NC(=C(N1C)Br)C(F)(F)F)OCC MWXDWVWIRFDRAC-UHFFFAOYSA-N 0.000 description 2
- CUAPJFZSLQXCBK-UHFFFAOYSA-N 5-bromo-2-ethenyl-3-methylimidazole-4-carboxylic acid Chemical compound BrC=1N=C(N(C1C(=O)O)C)C=C CUAPJFZSLQXCBK-UHFFFAOYSA-N 0.000 description 2
- KTOITQDNBDISTH-UHFFFAOYSA-N 5-bromo-6-chloro-1h-indazol-3-amine Chemical compound ClC1=C(Br)C=C2C(N)=NNC2=C1 KTOITQDNBDISTH-UHFFFAOYSA-N 0.000 description 2
- ZLVYBBARUGUARK-UHFFFAOYSA-N 5-chloro-3-propan-2-ylimidazole-4-carboxylic acid Chemical compound CC(C)N1C=NC(Cl)=C1C(O)=O ZLVYBBARUGUARK-UHFFFAOYSA-N 0.000 description 2
- YRRNBRSIKSOZDE-UHFFFAOYSA-N 5-fluoro-3-methylimidazole-4-carboxylic acid Chemical compound Cn1cnc(F)c1C(O)=O YRRNBRSIKSOZDE-UHFFFAOYSA-N 0.000 description 2
- RBCNIWARSKCBGQ-UHFFFAOYSA-N 5-tert-butyl-2-chloro-4-methylbenzonitrile Chemical compound CC1=C(C=C(C#N)C(Cl)=C1)C(C)(C)C RBCNIWARSKCBGQ-UHFFFAOYSA-N 0.000 description 2
- GDYQJSUNJSFWAU-UHFFFAOYSA-N 6-chloro-5-ethenyl-1H-indazol-3-amine Chemical compound C=CC1=CC2=C(C=C1Cl)NN=C2N GDYQJSUNJSFWAU-UHFFFAOYSA-N 0.000 description 2
- FMFHIFLARWRUNF-UHFFFAOYSA-N 6-tert-butyl-3,5-dichloro-1H-pyridin-2-one Chemical compound C(C)(C)(C)C1=C(C=C(C(=N1)O)Cl)Cl FMFHIFLARWRUNF-UHFFFAOYSA-N 0.000 description 2
- UURBMOPFXIACEU-UHFFFAOYSA-N 6-tert-butyl-3,5-dichloropyridine-2-carbonitrile Chemical compound CC(C)(C)C1=C(C=C(C(=N1)C#N)Cl)Cl UURBMOPFXIACEU-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NIVLGYCEZKPJHS-UHFFFAOYSA-N N-(2-bromo-4-chloro-5-propan-2-ylphenyl)acetamide Chemical compound CC(C)C1=CC(=C(C=C1Cl)Br)NC(=O)C NIVLGYCEZKPJHS-UHFFFAOYSA-N 0.000 description 2
- BVHJFJWUZYDDIC-UHFFFAOYSA-N N-(2-bromo-5-tert-butylphenyl)acetamide Chemical compound BrC1=C(C=C(C=C1)C(C)(C)C)NC(C)=O BVHJFJWUZYDDIC-UHFFFAOYSA-N 0.000 description 2
- NPYITNSDUWJPBJ-UHFFFAOYSA-N N-(4-bromo-5-tert-butyl-2-chlorophenyl)acetamide Chemical compound BrC1=CC(=C(C=C1C(C)(C)C)NC(C)=O)Cl NPYITNSDUWJPBJ-UHFFFAOYSA-N 0.000 description 2
- UFQMHPVFJPIJHK-UHFFFAOYSA-N N-(4-chloro-3-propan-2-ylphenyl)acetamide Chemical compound CC(C)C1=C(C=CC(=C1)NC(=O)C)Cl UFQMHPVFJPIJHK-UHFFFAOYSA-N 0.000 description 2
- QTWCMLUECIXIKU-UHFFFAOYSA-N N-(5-bromo-6-chloro-1H-indazol-3-yl)acetamide Chemical compound BrC=1C=C2C(=NNC2=CC1Cl)NC(C)=O QTWCMLUECIXIKU-UHFFFAOYSA-N 0.000 description 2
- LODBDUJPJKPKCY-UHFFFAOYSA-N N-(5-tert-butyl-2-chloro-4-methylphenyl)acetamide Chemical compound CC1=CC(=C(C=C1C(C)(C)C)NC(=O)C)Cl LODBDUJPJKPKCY-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 2
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 150000001924 cycloalkanes Chemical class 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- MLYMKNBAQUPBOO-UHFFFAOYSA-N dimethyl 1-propan-2-ylimidazole-4,5-dicarboxylate Chemical compound COC(=O)C=1N=CN(C(C)C)C=1C(=O)OC MLYMKNBAQUPBOO-UHFFFAOYSA-N 0.000 description 2
- XBIPBYUBAYFWLY-UHFFFAOYSA-N dimethyl 2-bromo-1-methylimidazole-4,5-dicarboxylate Chemical compound BrC=1N(C(=C(N1)C(=O)OC)C(=O)OC)C XBIPBYUBAYFWLY-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- LTOQPXPLDXOABT-BJMVGYQFSA-N ethyl (3e)-2-chloro-3-(methoxycarbonylhydrazinylidene)butanoate Chemical compound CCOC(=O)C(Cl)C(\C)=N\NC(=O)OC LTOQPXPLDXOABT-BJMVGYQFSA-N 0.000 description 2
- IZGLDAAVEWBNER-UHFFFAOYSA-N ethyl 2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-methyl-3-(2,2,2-trifluoroethyl)imidazole-4-carboxylate Chemical compound [Si](C)(C)(C(C)(C)C)OCC=1N(C(=C(N1)C)C(=O)OCC)CC(F)(F)F IZGLDAAVEWBNER-UHFFFAOYSA-N 0.000 description 2
- YVJZJAJAGZNKMY-UHFFFAOYSA-N ethyl 2-bromo-3-propan-2-yl-5-(trifluoromethyl)imidazole-4-carboxylate Chemical compound CCOC(=O)C1=C(N=C(N1C(C)C)Br)C(F)(F)F YVJZJAJAGZNKMY-UHFFFAOYSA-N 0.000 description 2
- OBFIZSPFBNULEK-UHFFFAOYSA-N ethyl 2-ethenyl-3-propan-2-yl-5-(trifluoromethyl)imidazole-4-carboxylate Chemical compound CCOC(=O)C1=C(N=C(N1C(C)C)C=C)C(F)(F)F OBFIZSPFBNULEK-UHFFFAOYSA-N 0.000 description 2
- ZRDOKPWVBHDGHJ-UHFFFAOYSA-N ethyl 3-cyclopropyl-5-methylimidazole-4-carboxylate Chemical compound CCOC(=O)C1=C(N=CN1C2CC2)C ZRDOKPWVBHDGHJ-UHFFFAOYSA-N 0.000 description 2
- SQOGOQOITFUZNT-UHFFFAOYSA-N ethyl 4-chloro-2,5-dimethylpyrazole-3-carboxylate Chemical compound CCOC(=O)C1=C(Cl)C(C)=NN1C SQOGOQOITFUZNT-UHFFFAOYSA-N 0.000 description 2
- FNFMBVQIFWBJPN-UHFFFAOYSA-N ethyl 4-cyano-1h-imidazole-5-carboxylate Chemical compound CCOC(=O)C=1NC=NC=1C#N FNFMBVQIFWBJPN-UHFFFAOYSA-N 0.000 description 2
- WUWBXROZAMCTTN-UHFFFAOYSA-N ethyl 5-(bromomethyl)-4-chloro-2-methylpyrazole-3-carboxylate Chemical compound CCOC(=O)C1=C(C(=NN1C)CBr)Cl WUWBXROZAMCTTN-UHFFFAOYSA-N 0.000 description 2
- UFVZJVCFLDHTDP-UHFFFAOYSA-N ethyl 5-cyano-3-methylimidazole-4-carboxylate Chemical compound C(C)OC(=O)C1=C(N=CN1C)C#N UFVZJVCFLDHTDP-UHFFFAOYSA-N 0.000 description 2
- WYCYKJRUORMBEE-UHFFFAOYSA-N ethyl 5-methyl-3-propan-2-ylimidazole-4-carboxylate Chemical compound CCOC(=O)c1c(C)ncn1C(C)C WYCYKJRUORMBEE-UHFFFAOYSA-N 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- UYVXZUTYZGILQG-UHFFFAOYSA-N methoxyboronic acid Chemical compound COB(O)O UYVXZUTYZGILQG-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- XIBWGVSDFAOMBV-BJMVGYQFSA-N methyl (3E)-2-chloro-3-(methoxycarbonylhydrazinylidene)pentanoate Chemical compound CC/C(=N\NC(=O)OC)/C(C(=O)OC)Cl XIBWGVSDFAOMBV-BJMVGYQFSA-N 0.000 description 2
- GZZUUHHVKJJFKF-UHFFFAOYSA-N methyl 2,5-dibromo-1h-imidazole-4-carboxylate Chemical compound COC(=O)C=1N=C(Br)NC=1Br GZZUUHHVKJJFKF-UHFFFAOYSA-N 0.000 description 2
- FEXBHFZPLXHJAK-UHFFFAOYSA-N methyl 2,5-dibromo-3-methylimidazole-4-carboxylate Chemical compound COC(=O)C1=C(Br)N=C(Br)N1C FEXBHFZPLXHJAK-UHFFFAOYSA-N 0.000 description 2
- UUKJSJIBRZCCPV-UHFFFAOYSA-N methyl 2,5-diiodo-3-methylimidazole-4-carboxylate Chemical compound COC(=O)C=1N(C(=NC1I)I)C UUKJSJIBRZCCPV-UHFFFAOYSA-N 0.000 description 2
- OHAIIBYBMSUMSS-UHFFFAOYSA-N methyl 2-(1-acetyloxyethenyl)-3-methylimidazole-4-carboxylate Chemical compound CC(=O)OC(=C)C1=NC=C(N1C)C(=O)OC OHAIIBYBMSUMSS-UHFFFAOYSA-N 0.000 description 2
- PRRPUSNWDRPKLK-UHFFFAOYSA-N methyl 2-(1-chloroethyl)-3-methylimidazole-4-carboxylate Chemical compound CC(C1=NC=C(N1C)C(=O)OC)Cl PRRPUSNWDRPKLK-UHFFFAOYSA-N 0.000 description 2
- FYDLECIKUFOCJR-UHFFFAOYSA-N methyl 2-(1-hydroxyethyl)-3-methylimidazole-4-carboxylate Chemical compound OC(C)C1=NC=C(N1C)C(=O)OC FYDLECIKUFOCJR-UHFFFAOYSA-N 0.000 description 2
- IOLACTRUZAJNRX-UHFFFAOYSA-N methyl 2-(hydroxymethyl)-3-methylimidazole-4-carboxylate Chemical compound COC(=O)C1=CN=C(CO)N1C IOLACTRUZAJNRX-UHFFFAOYSA-N 0.000 description 2
- MBUWOMXRHIRMEU-UHFFFAOYSA-N methyl 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-(difluoromethyl)-3-methylimidazole-4-carboxylate Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C)C(=O)OC)C(F)F)Cl MBUWOMXRHIRMEU-UHFFFAOYSA-N 0.000 description 2
- RODRTXGKAYYSBL-UHFFFAOYSA-N methyl 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-methylimidazole-4-carboxylate Chemical compound C(C)(C)(C)C=1C=C2C(=NNC2=CC1Cl)NCC=1N(C(=C(N1)Cl)C(=O)OC)C RODRTXGKAYYSBL-UHFFFAOYSA-N 0.000 description 2
- DZDUSPNLYPPDIM-UHFFFAOYSA-N methyl 2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-ethyl-3-methylimidazole-4-carboxylate Chemical compound CCC1=C(N(C(=N1)CO[Si](C)(C)C(C)(C)C)C)C(=O)OC DZDUSPNLYPPDIM-UHFFFAOYSA-N 0.000 description 2
- OCBHDOMBVDQIEZ-UHFFFAOYSA-N methyl 2-acetyl-3-methylimidazole-4-carboxylate Chemical compound C(C)(=O)C1=NC=C(N1C)C(=O)OC OCBHDOMBVDQIEZ-UHFFFAOYSA-N 0.000 description 2
- SMXZXTSYEHMIJQ-UHFFFAOYSA-N methyl 2-bromo-5-(difluoromethyl)-3-methylimidazole-4-carboxylate Chemical compound CN1C(=C(N=C1Br)C(F)F)C(=O)OC SMXZXTSYEHMIJQ-UHFFFAOYSA-N 0.000 description 2
- AJHWQYIKHXWBFL-UHFFFAOYSA-N methyl 2-bromo-5-chloro-3-methylimidazole-4-carboxylate Chemical compound COC(=O)c1c(Cl)nc(Br)n1C AJHWQYIKHXWBFL-UHFFFAOYSA-N 0.000 description 2
- MGAWGVXMGWEQDC-UHFFFAOYSA-N methyl 2-bromo-5-formyl-3-methylimidazole-4-carboxylate Chemical compound CN1C(=C(N=C1Br)C=O)C(=O)OC MGAWGVXMGWEQDC-UHFFFAOYSA-N 0.000 description 2
- SWLCZEZEPBYTMD-UHFFFAOYSA-N methyl 2-ethenyl-5-iodo-3-methylimidazole-4-carboxylate Chemical compound CN1C(=NC(=C1C(=O)OC)I)C=C SWLCZEZEPBYTMD-UHFFFAOYSA-N 0.000 description 2
- XSVVORFWPGPINR-UHFFFAOYSA-N methyl 2-formyl-3-methylimidazole-4-carboxylate Chemical compound COC(=O)C1=CN=C(C=O)N1C XSVVORFWPGPINR-UHFFFAOYSA-N 0.000 description 2
- YEOIUBSTEMRCKZ-UHFFFAOYSA-N methyl 5-(difluoromethyl)-2-formyl-3-methylimidazole-4-carboxylate Chemical compound CN1C(=NC(=C1C(=O)OC)C(F)F)C=O YEOIUBSTEMRCKZ-UHFFFAOYSA-N 0.000 description 2
- VJEJPIYIGUHOQS-UHFFFAOYSA-N methyl 5-bromo-2-ethenyl-3-methylimidazole-4-carboxylate Chemical compound CN1C(=NC(=C1C(=O)OC)Br)C=C VJEJPIYIGUHOQS-UHFFFAOYSA-N 0.000 description 2
- KCHYHLLGPDNORK-UHFFFAOYSA-N methyl 5-chloro-2-formyl-3-methylimidazole-4-carboxylate Chemical compound CN1C(=NC(=C1C(=O)OC)Cl)C=O KCHYHLLGPDNORK-UHFFFAOYSA-N 0.000 description 2
- BWCSVMWBSKPYBM-UHFFFAOYSA-N methyl 5-chloro-3-propan-2-ylimidazole-4-carboxylate Chemical compound ClC=1N=CN(C1C(=O)OC)C(C)C BWCSVMWBSKPYBM-UHFFFAOYSA-N 0.000 description 2
- DKVMACIFGOENFJ-UHFFFAOYSA-N methyl 5-fluoro-1h-imidazole-4-carboxylate Chemical compound COC(=O)C=1N=CNC=1F DKVMACIFGOENFJ-UHFFFAOYSA-N 0.000 description 2
- PFTAMBSNWREKGG-UHFFFAOYSA-N methyl 5-fluoro-3-methylimidazole-4-carboxylate Chemical compound FC=1N=CN(C1C(=O)OC)C PFTAMBSNWREKGG-UHFFFAOYSA-N 0.000 description 2
- IDRNZLYHSBNEQM-UHFFFAOYSA-N methyl 5-formyl-3-propan-2-ylimidazole-4-carboxylate Chemical compound CC(C)N1C=NC(=C1C(=O)OC)C=O IDRNZLYHSBNEQM-UHFFFAOYSA-N 0.000 description 2
- WFJRIDQGVSJLLH-UHFFFAOYSA-N methyl n-aminocarbamate Chemical compound COC(=O)NN WFJRIDQGVSJLLH-UHFFFAOYSA-N 0.000 description 2
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- XTCIWRDRDQTIKK-UHFFFAOYSA-N n-(5-tert-butyl-2-chlorophenyl)acetamide Chemical compound CC(=O)NC1=CC(C(C)(C)C)=CC=C1Cl XTCIWRDRDQTIKK-UHFFFAOYSA-N 0.000 description 2
- QUQLDSFMMZCQHF-UHFFFAOYSA-N n-(6-chloro-1h-indazol-3-yl)acetamide Chemical compound ClC1=CC=C2C(NC(=O)C)=NNC2=C1 QUQLDSFMMZCQHF-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- RWGNEOUYYQBMEW-UHFFFAOYSA-M sodium 2-formyl-3-methylimidazole-4-carboxylate Chemical compound CN1C(=CN=C1C=O)C(=O)[O-].[Na+] RWGNEOUYYQBMEW-UHFFFAOYSA-M 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- MNAZNLTZPUCLNB-BDAKNGLRSA-N tert-butyl (3R,4R)-3-azido-4-(cyanomethyl)pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@@H]([C@@H](C1)CC#N)N=[N+]=[N-] MNAZNLTZPUCLNB-BDAKNGLRSA-N 0.000 description 2
- TZTVZEMZVITDRW-SFYZADRCSA-N tert-butyl (3R,4R)-3-azido-4-(fluoromethyl)pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@@H]([C@@H](C1)CF)N=[N+]=[N-] TZTVZEMZVITDRW-SFYZADRCSA-N 0.000 description 2
- GVMGNVGDJJVIGC-YUMQZZPRSA-N tert-butyl (3R,4R)-3-azido-4-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]([C@H](C1)N=[N+]=[N-])CO GVMGNVGDJJVIGC-YUMQZZPRSA-N 0.000 description 2
- BEWGRBOGWYMYLA-IUCAKERBSA-N tert-butyl (3R,4R)-3-azido-4-(methoxymethyl)pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@@H]([C@@H](C1)COC)N=[N+]=[N-] BEWGRBOGWYMYLA-IUCAKERBSA-N 0.000 description 2
- AWQMYQMEJVARSU-IUCAKERBSA-N tert-butyl (3R,4R)-3-azido-4-(methylsulfonyloxymethyl)pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@@H]([C@@H](C1)COS(=O)(=O)C)N=[N+]=[N-] AWQMYQMEJVARSU-IUCAKERBSA-N 0.000 description 2
- ITMWCSZKLUDZSX-ZJUUUORDSA-N tert-butyl (3R,4R)-3-azido-4-[(dimethylamino)methyl]pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@@H]([C@@H](C1)CN(C)C)N=[N+]=[N-] ITMWCSZKLUDZSX-ZJUUUORDSA-N 0.000 description 2
- YYEQNVMSUVBAHQ-STQMWFEESA-N tert-butyl (3R,4R)-3-azido-4-[[tert-butyl(dimethyl)silyl]oxymethyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]([C@H](C1)N=[N+]=[N-])CO[Si](C)(C)C(C)(C)C YYEQNVMSUVBAHQ-STQMWFEESA-N 0.000 description 2
- CHZMTYJWURGDSB-RKDXNWHRSA-N tert-butyl (3R,4S)-3-(cyanomethyl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound C(#N)C[C@@H]1CN(C[C@H]1O)C(=O)OC(C)(C)C CHZMTYJWURGDSB-RKDXNWHRSA-N 0.000 description 2
- PBRXHMHVWRYNFE-NXEZZACHSA-N tert-butyl (3R,4S)-3-(cyanomethyl)-4-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@H]([C@@H](C1)OS(=O)(=O)C)CC#N PBRXHMHVWRYNFE-NXEZZACHSA-N 0.000 description 2
- ZLASHXUGBCPHRL-HTQZYQBOSA-N tert-butyl (3R,4S)-3-(fluoromethyl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]([C@@H](C1)O)CF ZLASHXUGBCPHRL-HTQZYQBOSA-N 0.000 description 2
- NHBVZYSVYLSKRA-RKDXNWHRSA-N tert-butyl (3R,4S)-3-(fluoromethyl)-4-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]([C@@H](C1)OS(=O)(=O)C)CF NHBVZYSVYLSKRA-RKDXNWHRSA-N 0.000 description 2
- DUVDLEKJLWZNRF-VHSXEESVSA-N tert-butyl (3S,4S)-3-(methoxymethyl)-4-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@H]([C@@H](C1)OS(=O)(=O)C)COC DUVDLEKJLWZNRF-VHSXEESVSA-N 0.000 description 2
- DIEZMZHMLUOTLK-QWHCGFSZSA-N tert-butyl (3S,4S)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]([C@@H](C1)O)CO[Si](C)(C)C(C)(C)C DIEZMZHMLUOTLK-QWHCGFSZSA-N 0.000 description 2
- HKFBMXSNXQWPBE-UONOGXRCSA-N tert-butyl (3S,4S)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]([C@@H](C1)OS(=O)(=O)C)CO[Si](C)(C)C(C)(C)C HKFBMXSNXQWPBE-UONOGXRCSA-N 0.000 description 2
- NRWCGXRROLHAGQ-DTWKUNHWSA-N tert-butyl (3S,4S)-3-hydroxy-4-(methoxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]([C@@H](C1)O)COC NRWCGXRROLHAGQ-DTWKUNHWSA-N 0.000 description 2
- BSTWKRUNXOFBPE-JGVFFNPUSA-N tert-butyl (3s,4s)-3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@@H](O)[C@H](CO)C1 BSTWKRUNXOFBPE-JGVFFNPUSA-N 0.000 description 2
- PKBLKENCVPGTRF-UHFFFAOYSA-N tert-butyl 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-3,5-dimethylimidazole-4-carboxylate Chemical compound C(C)(C)(C)C=1C=C2C(=NNC2=CC1Cl)NCC=1N(C(=C(N1)C)C(=O)OC(C)(C)C)C PKBLKENCVPGTRF-UHFFFAOYSA-N 0.000 description 2
- OCXSSEMIKUAUIR-UHFFFAOYSA-N tert-butyl 2-formyl-3,5-dimethylimidazole-4-carboxylate Chemical compound CC1=C(N(C(=N1)C=O)C)C(=O)OC(C)(C)C OCXSSEMIKUAUIR-UHFFFAOYSA-N 0.000 description 2
- LPUKFFKAQFBJRK-UHFFFAOYSA-N tert-butyl 3,5-dimethylimidazole-4-carboxylate Chemical compound CN1C=NC(=C1C(=O)OC(C)(C)C)C LPUKFFKAQFBJRK-UHFFFAOYSA-N 0.000 description 2
- GGFCXATYHILPAM-UHFFFAOYSA-N tert-butyl 3-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-5-bromo-6-chloroindazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N(C1=NN(C2=CC(=C(C=C12)Br)Cl)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C GGFCXATYHILPAM-UHFFFAOYSA-N 0.000 description 2
- ITUFCMNLAJPITO-UHFFFAOYSA-N tert-butyl 3-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-6-chloro-5-[1-(trifluoromethyl)cyclopropyl]indazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N(C1=NN(C2=CC(=C(C=C12)C1(CC1)C(F)(F)F)Cl)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C ITUFCMNLAJPITO-UHFFFAOYSA-N 0.000 description 2
- ILJMTUGRFCDXMO-UHFFFAOYSA-N tert-butyl 3-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-6-chloro-5-[5-(trifluoromethyl)-3,4-dihydropyrazol-5-yl]indazole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C2=CC(=C(C=C2C(=N1)N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C3(CCN=N3)C(F)(F)F)Cl ILJMTUGRFCDXMO-UHFFFAOYSA-N 0.000 description 2
- GTWPTHAFEZMQGK-UHFFFAOYSA-N tert-butyl 5-fluoro-2-formyl-3-methylimidazole-4-carboxylate Chemical compound CC(C)(C)OC(=O)C1=C(N=C(N1C)C=O)F GTWPTHAFEZMQGK-UHFFFAOYSA-N 0.000 description 2
- AAIYEZMDRXEENN-UHFFFAOYSA-N tert-butyl 5-fluoro-3-methylimidazole-4-carboxylate Chemical compound CC(C)(C)OC(=O)C1=C(N=CN1C)F AAIYEZMDRXEENN-UHFFFAOYSA-N 0.000 description 2
- VKJIAQGBWLIDOB-UHFFFAOYSA-N tert-butyl N-(1-prop-2-enoylazetidin-3-yl)carbamate Chemical compound C(C=C)(=O)N1CC(C1)NC(OC(C)(C)C)=O VKJIAQGBWLIDOB-UHFFFAOYSA-N 0.000 description 2
- BGVHWUBNFNOWAN-UHFFFAOYSA-N tert-butyl N-(4,4-difluoro-1-prop-2-enoylpyrrolidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CN(CC1(F)F)C(=O)C=C BGVHWUBNFNOWAN-UHFFFAOYSA-N 0.000 description 2
- RERBXVVJBYDDCO-ZJUUUORDSA-N tert-butyl N-[(3R,4R)-4-methyl-1-prop-2-enoylpyrrolidin-3-yl]carbamate Chemical compound C[C@@H]1CN(C[C@@H]1NC(=O)OC(C)(C)C)C(=O)C=C RERBXVVJBYDDCO-ZJUUUORDSA-N 0.000 description 2
- CQUUQNBQJWHKDF-JTQLQIEISA-N tert-butyl N-[(7R)-5-prop-2-enoyl-5-azaspiro[2.4]heptan-7-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CN(CC12CC2)C(=O)C=C CQUUQNBQJWHKDF-JTQLQIEISA-N 0.000 description 2
- FESDUDPSRMWIDL-UHFFFAOYSA-N tert-butyl n,n'-di(propan-2-yl)carbamimidate Chemical compound CC(C)NC(OC(C)(C)C)=NC(C)C FESDUDPSRMWIDL-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 description 1
- 125000006736 (C6-C20) aryl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- IIJSFQFJZAEKHB-UHFFFAOYSA-M 1,3-dimethylimidazol-1-ium;chloride Chemical compound [Cl-].CN1C=C[N+](C)=C1 IIJSFQFJZAEKHB-UHFFFAOYSA-M 0.000 description 1
- BPPVVYPZWKVZFH-UHFFFAOYSA-N 1-(4-amino-3,3-difluoropyrrolidin-1-yl)prop-2-en-1-one 2,2,2-trifluoroacetic acid Chemical compound C=CC(=O)N1CC(C(C1)(F)F)N.C(=O)(C(F)(F)F)O BPPVVYPZWKVZFH-UHFFFAOYSA-N 0.000 description 1
- DMELLJARUNXECC-ZETCQYMHSA-N 1-[(7R)-7-amino-5-azaspiro[2.4]heptan-5-yl]prop-2-en-1-one Chemical compound N[C@H]1CN(CC11CC1)C(C=C)=O DMELLJARUNXECC-ZETCQYMHSA-N 0.000 description 1
- XHCAGOVGSDHHNP-UHFFFAOYSA-N 1-bromo-4-tert-butylbenzene Chemical compound CC(C)(C)C1=CC=C(Br)C=C1 XHCAGOVGSDHHNP-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LYFNAJACLPGPIK-UHFFFAOYSA-N 1-methyl-4-(trifluoromethyl)imidazole Chemical compound CN1C=NC(C(F)(F)F)=C1 LYFNAJACLPGPIK-UHFFFAOYSA-N 0.000 description 1
- SUOVGHDPXJUFME-UHFFFAOYSA-N 1-methylimidazole-4,5-dicarbonitrile Chemical compound CN1C=NC(C#N)=C1C#N SUOVGHDPXJUFME-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- OEUFULRURWNKHP-UHFFFAOYSA-N 2-(diethoxymethyl)-3-methyl-5-(trifluoromethyl)imidazole-4-carboxylic acid Chemical compound C(C)OC(C=1N(C(=C(N1)C(F)(F)F)C(=O)O)C)OCC OEUFULRURWNKHP-UHFFFAOYSA-N 0.000 description 1
- BRIKVTYQMKVQAO-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-3,5-dimethylimidazole-4-carboxylic acid Chemical compound C(C)(C)(C)C=1C=C2C(=NNC2=CC1Cl)NCC=1N(C(=C(N1)C)C(=O)O)C BRIKVTYQMKVQAO-UHFFFAOYSA-N 0.000 description 1
- XJYRNPHOWYINRL-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-(difluoromethyl)-3-methylimidazole-4-carboxylic acid Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C)C(=O)O)C(F)F)Cl XJYRNPHOWYINRL-UHFFFAOYSA-N 0.000 description 1
- RWJXJRBEAJZGIY-UHFFFAOYSA-N 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-chloro-3-methylimidazole-4-carboxylic acid Chemical compound CC(C)(C)C1=C(C=C2C(=C1)C(=NN2)NCC3=NC(=C(N3C)C(=O)O)Cl)Cl RWJXJRBEAJZGIY-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- WICCUXQFUQIBSY-UHFFFAOYSA-N 2-ethenyl-3-propan-2-yl-5-(trifluoromethyl)imidazole-4-carboxylic acid Chemical compound C(C)(C)N1C(=NC(=C1C(=O)O)C(F)(F)F)C=C WICCUXQFUQIBSY-UHFFFAOYSA-N 0.000 description 1
- CDZCZDWBECKRKA-UHFFFAOYSA-N 2-ethoxycarbonyl-1,3-thiazole-4-carboxylic acid Chemical compound CCOC(=O)C1=NC(C(O)=O)=CS1 CDZCZDWBECKRKA-UHFFFAOYSA-N 0.000 description 1
- NFSJIZZKUYLNGY-UHFFFAOYSA-N 2-formyl-3-methyl-N-(1-prop-2-enoylazetidin-3-yl)imidazole-4-carboxamide Chemical compound CN1C(=CN=C1C=O)C(=O)NC2CN(C2)C(=O)C=C NFSJIZZKUYLNGY-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- RDDNUXKQKYWZGT-UHFFFAOYSA-N 3-cyclopropyl-5-methylimidazole-4-carboxylic acid Chemical compound OC(=O)C1=C(C)N=CN1C1CC1 RDDNUXKQKYWZGT-UHFFFAOYSA-N 0.000 description 1
- XCCNRBCNYGWTQX-UHFFFAOYSA-N 3-propan-2-ylaniline Chemical compound CC(C)C1=CC=CC(N)=C1 XCCNRBCNYGWTQX-UHFFFAOYSA-N 0.000 description 1
- FIZGQEOFMPVHJY-UHFFFAOYSA-N 3-tert-butyl-5-methylimidazole-4-carboxylic acid Chemical compound CC=1N=CN(C(C)(C)C)C=1C(O)=O FIZGQEOFMPVHJY-UHFFFAOYSA-N 0.000 description 1
- DPKTVUKEPNBABS-UHFFFAOYSA-N 3-tert-butylaniline Chemical compound CC(C)(C)C1=CC=CC(N)=C1 DPKTVUKEPNBABS-UHFFFAOYSA-N 0.000 description 1
- GGSSZVWESZQFOZ-UHFFFAOYSA-N 4,4,6-trimethyl-2-(3,3,3-trifluoroprop-1-en-2-yl)-1,3,2-dioxaborinane Chemical compound CC1CC(C)(C)OB(C(=C)C(F)(F)F)O1 GGSSZVWESZQFOZ-UHFFFAOYSA-N 0.000 description 1
- HEPOBHPBDBPLJI-UHFFFAOYSA-N 5-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-2,4-dimethylpyrazole-3-carboxylic acid Chemical compound C(C)(C)(C)C=1C=C2C(=NNC2=CC1Cl)NCC1=NN(C(=C1C)C(=O)O)C HEPOBHPBDBPLJI-UHFFFAOYSA-N 0.000 description 1
- HLPLZPCHAFAVAN-MRVPVSSYSA-N 5-chloro-3-[(3R)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]imidazole-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC[C@H](C1)N2C=NC(=C2C(=O)O)Cl HLPLZPCHAFAVAN-MRVPVSSYSA-N 0.000 description 1
- VLDIILVESKLJFS-UHFFFAOYSA-N 5-chloro-3-methylimidazole-4-carboxylic acid Chemical compound CN1C=NC(Cl)=C1C(O)=O VLDIILVESKLJFS-UHFFFAOYSA-N 0.000 description 1
- ZKRPZVXOCOLIFW-UHFFFAOYSA-N 5-cyano-3-methylimidazole-4-carboxylic acid Chemical compound CN1C=NC(C#N)=C1C(O)=O ZKRPZVXOCOLIFW-UHFFFAOYSA-N 0.000 description 1
- YYGMEUGJPKGHBP-UHFFFAOYSA-N 5-ethoxycarbonyl-2-methylpyrazole-3-carboxylic acid Chemical compound CCOC(=O)C=1C=C(C(O)=O)N(C)N=1 YYGMEUGJPKGHBP-UHFFFAOYSA-N 0.000 description 1
- CAOQQTCJTOGWBY-UHFFFAOYSA-N 5-ethyl-2-(hydroxymethyl)-3-methylimidazole-4-carboxylic acid Chemical compound C(C)C1=C(N(C(=N1)CO)C)C(=O)O CAOQQTCJTOGWBY-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- RJVIKLWJEXVGEO-UHFFFAOYSA-N 5-tert-butyl-1h-indazol-3-amine Chemical compound CC(C)(C)C1=CC=C2NN=C(N)C2=C1 RJVIKLWJEXVGEO-UHFFFAOYSA-N 0.000 description 1
- GBEZQVUTKPATBG-UHFFFAOYSA-N 5-tert-butyl-6-chloro-1H-pyrazolo[4,3-b]pyridin-3-amine Chemical compound C(C)(C)(C)C1=C(C=C2C(=N1)C(=NN2)N)Cl GBEZQVUTKPATBG-UHFFFAOYSA-N 0.000 description 1
- PTYVLFWXGFQZEZ-UHFFFAOYSA-N 5-tert-butyl-6-methyl-1H-indazol-3-amine Chemical compound C(C)(C)(C)C=1C=C2C(=NNC2=CC1C)N PTYVLFWXGFQZEZ-UHFFFAOYSA-N 0.000 description 1
- BPTYMRSBTUERSW-UHFFFAOYSA-N 6-chloro-1h-indazol-3-amine Chemical compound ClC1=CC=C2C(N)=NNC2=C1 BPTYMRSBTUERSW-UHFFFAOYSA-N 0.000 description 1
- CSIJEYBQQWQAQY-UHFFFAOYSA-N 6-chloro-5-(3,3,3-trifluoroprop-1-en-2-yl)-1H-indazol-3-amine Chemical compound C=C(C1=C(C=C2C(=C1)C(=NN2)N)Cl)C(F)(F)F CSIJEYBQQWQAQY-UHFFFAOYSA-N 0.000 description 1
- COIWXMUFVQFFLR-UHFFFAOYSA-N 6-chloro-5-[1-(trifluoromethyl)cyclopropyl]-1H-indazol-3-amine Chemical compound ClC1=C(C=C2C(=NNC2=C1)N)C1(CC1)C(F)(F)F COIWXMUFVQFFLR-UHFFFAOYSA-N 0.000 description 1
- OKMLAYPGCLESGB-UHFFFAOYSA-N 6-chloro-5-ethyl-1H-indazol-3-amine Chemical compound CCC1=CC2=C(C=C1Cl)NN=C2N OKMLAYPGCLESGB-UHFFFAOYSA-N 0.000 description 1
- IYBOMORRUXLZRK-UHFFFAOYSA-N 6-chloro-5-methyl-1H-indazol-3-amine Chemical compound CC1=CC2=C(C=C1Cl)NN=C2N IYBOMORRUXLZRK-UHFFFAOYSA-N 0.000 description 1
- NLERWJHDZPYYCR-UHFFFAOYSA-N 6-chloro-5-propan-2-yl-1H-indazol-3-amine Chemical compound CC(C)C1=C(C=C2C(=C1)C(=NN2)N)Cl NLERWJHDZPYYCR-UHFFFAOYSA-N 0.000 description 1
- KEBYYKZCEJVXIG-UHFFFAOYSA-N 6-tert-butyl-1h-pyridin-2-one Chemical compound CC(C)(C)C1=CC=CC(=O)N1 KEBYYKZCEJVXIG-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- CVTRUXCIVXJZNF-UHFFFAOYSA-N N-(2-chloro-5-propan-2-ylphenyl)acetamide Chemical compound ClC1=C(C=C(C=C1)C(C)C)NC(C)=O CVTRUXCIVXJZNF-UHFFFAOYSA-N 0.000 description 1
- VTXYTXUKXPZMCY-UHFFFAOYSA-N N-(3-tert-butyl-4-chlorophenyl)acetamide Chemical compound C(C)(C)(C)C=1C=C(C=CC1Cl)NC(C)=O VTXYTXUKXPZMCY-UHFFFAOYSA-N 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 1
- 108050004017 Ras GTPase-activating protein 1 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000057028 SOS1 Human genes 0.000 description 1
- 108700022176 SOS1 Proteins 0.000 description 1
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 101150100839 Sos1 gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QYCSNMDOZNUZIT-UHFFFAOYSA-N benzhydrylidenehydrazine Chemical compound C=1C=CC=CC=1C(=NN)C1=CC=CC=C1 QYCSNMDOZNUZIT-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006226 butoxyethyl group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000003113 cycloheptyloxy group Chemical group C1(CCCCCC1)O* 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MBWXLICVQZUJOW-UHFFFAOYSA-N diethyl 1h-pyrazole-3,5-dicarboxylate Chemical compound CCOC(=O)C=1C=C(C(=O)OCC)NN=1 MBWXLICVQZUJOW-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- CUIWFAXEALIQJS-UHFFFAOYSA-N dimethyl 1h-imidazole-4,5-dicarboxylate Chemical compound COC(=O)C=1N=CNC=1C(=O)OC CUIWFAXEALIQJS-UHFFFAOYSA-N 0.000 description 1
- JMXUWJPKHDKROF-UHFFFAOYSA-N dimethyl 2-bromo-1h-imidazole-4,5-dicarboxylate Chemical compound COC(=O)C=1N=C(Br)NC=1C(=O)OC JMXUWJPKHDKROF-UHFFFAOYSA-N 0.000 description 1
- AXAZMDOAUQTMOW-UHFFFAOYSA-N dimethylzinc Chemical compound C[Zn]C AXAZMDOAUQTMOW-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- RCRYEYMHBHPZQD-UHFFFAOYSA-N ditert-butyl-[2,3,4,5-tetramethyl-6-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=C(C)C(C)=C(C)C(C)=C1P(C(C)(C)C)C(C)(C)C RCRYEYMHBHPZQD-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- ZYSGPOXVDOROJU-UHFFFAOYSA-N ethyl 2,5-dimethylpyrazole-3-carboxylate Chemical compound CCOC(=O)C1=CC(C)=NN1C ZYSGPOXVDOROJU-UHFFFAOYSA-N 0.000 description 1
- VHSMVVWMAHWZER-UHFFFAOYSA-N ethyl 2-bromo-5-(trifluoromethyl)-1h-imidazole-4-carboxylate Chemical compound CCOC(=O)C=1NC(Br)=NC=1C(F)(F)F VHSMVVWMAHWZER-UHFFFAOYSA-N 0.000 description 1
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 1
- WBLOHVXNJJZLJY-UHFFFAOYSA-N ethyl 4-bromo-5-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-2-methylpyrazole-3-carboxylate Chemical compound C(C)(C)(C)C=1C=C2C(=NNC2=CC1Cl)NCC1=NN(C(=C1Br)C(=O)OCC)C WBLOHVXNJJZLJY-UHFFFAOYSA-N 0.000 description 1
- RDBFVTCQOMIUTM-UHFFFAOYSA-N ethyl 5-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-4-chloro-2-methylpyrazole-3-carboxylate Chemical compound CCOC(=O)C1=C(C(=NN1C)CNC2=NNC3=CC(=C(C=C32)C(C)(C)C)Cl)Cl RDBFVTCQOMIUTM-UHFFFAOYSA-N 0.000 description 1
- VLDUBDZWWNLZCU-UHFFFAOYSA-N ethyl 5-methyl-1h-imidazole-4-carboxylate Chemical compound CCOC(=O)C=1NC=NC=1C VLDUBDZWWNLZCU-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 125000006005 fluoroethoxy group Chemical group 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004871 hexylcarbonyl group Chemical group C(CCCCC)C(=O)* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000007031 hydroxymethylation reaction Methods 0.000 description 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 1
- JHBZAAACZVPPRQ-UHFFFAOYSA-L lithium;magnesium;2,2,6,6-tetramethylpiperidin-1-ide;dichloride Chemical compound [Li+].[Cl-].[Cl-].CC1(C)CCCC(C)(C)N1[Mg+] JHBZAAACZVPPRQ-UHFFFAOYSA-L 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- ULKSWZAXQDJMJT-UHFFFAOYSA-M magnesium;2,2,6,6-tetramethylpiperidin-1-ide;chloride Chemical compound [Cl-].CC1(C)CCCC(C)(C)N1[Mg+] ULKSWZAXQDJMJT-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- DVLGIQNHKLWSRU-UHFFFAOYSA-N methyl 1h-imidazole-5-carboxylate Chemical compound COC(=O)C1=CN=CN1 DVLGIQNHKLWSRU-UHFFFAOYSA-N 0.000 description 1
- RKJDXTMIJIKFOH-UHFFFAOYSA-N methyl 2-[1-[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]ethyl]-3-methylimidazole-4-carboxylate Chemical compound CC(C1=NC=C(N1C)C(=O)OC)NC2=NNC3=CC(=C(C=C32)C(C)(C)C)Cl RKJDXTMIJIKFOH-UHFFFAOYSA-N 0.000 description 1
- HQKDHMCNAMQTFI-UHFFFAOYSA-N methyl 2-chloro-3-oxopentanoate Chemical compound CCC(=O)C(Cl)C(=O)OC HQKDHMCNAMQTFI-UHFFFAOYSA-N 0.000 description 1
- PITWXZXKWWLRCK-UHFFFAOYSA-N methyl 2-formyl-5-iodo-3-methylimidazole-4-carboxylate Chemical compound CN1C(=NC(=C1C(=O)OC)I)C=O PITWXZXKWWLRCK-UHFFFAOYSA-N 0.000 description 1
- QSDBYBKUGLFFPU-SECBINFHSA-N methyl 5-chloro-2-formyl-3-[(3R)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]imidazole-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](C1)N2C(=NC(=C2C(=O)OC)Cl)C=O QSDBYBKUGLFFPU-SECBINFHSA-N 0.000 description 1
- OITMQTBDGAQVNY-SECBINFHSA-N methyl 5-chloro-3-[(3R)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]imidazole-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](C1)N2C=NC(=C2C(=O)OC)Cl OITMQTBDGAQVNY-SECBINFHSA-N 0.000 description 1
- OITMQTBDGAQVNY-VIFPVBQESA-N methyl 5-chloro-3-[(3S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]imidazole-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](C1)N2C=NC(=C2C(=O)OC)Cl OITMQTBDGAQVNY-VIFPVBQESA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000005185 naphthylcarbonyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- ZEJPMRKECMRICL-UHFFFAOYSA-N o-ethyl 2-amino-2-oxoethanethioate Chemical compound CCOC(=S)C(N)=O ZEJPMRKECMRICL-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- ANKYQOUREQLSLO-BDAKNGLRSA-N tert-butyl (3R,4R)-3-amino-4-(cyanomethyl)pyrrolidine-1-carboxylate Chemical compound N[C@H]1CN(C[C@H]1CC#N)C(=O)OC(C)(C)C ANKYQOUREQLSLO-BDAKNGLRSA-N 0.000 description 1
- QUKQPALDZPGNLB-SFYZADRCSA-N tert-butyl (3R,4R)-3-amino-4-(fluoromethyl)pyrrolidine-1-carboxylate Chemical compound N[C@H]1CN(C[C@H]1CF)C(=O)OC(C)(C)C QUKQPALDZPGNLB-SFYZADRCSA-N 0.000 description 1
- FCEKRQVFFRILLK-IUCAKERBSA-N tert-butyl (3R,4R)-3-amino-4-(methoxymethyl)pyrrolidine-1-carboxylate Chemical compound N[C@H]1CN(C[C@H]1COC)C(=O)OC(C)(C)C FCEKRQVFFRILLK-IUCAKERBSA-N 0.000 description 1
- DJTLNNRQIYVOOD-ZJUUUORDSA-N tert-butyl (3R,4R)-3-amino-4-[(dimethylamino)methyl]pyrrolidine-1-carboxylate Chemical compound N[C@H]1CN(C[C@H]1CN(C)C)C(=O)OC(C)(C)C DJTLNNRQIYVOOD-ZJUUUORDSA-N 0.000 description 1
- APCBTRDHCDOPNY-SSDOTTSWSA-N tert-butyl (3r)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)C1 APCBTRDHCDOPNY-SSDOTTSWSA-N 0.000 description 1
- APCBTRDHCDOPNY-ZETCQYMHSA-N tert-butyl (3s)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](O)C1 APCBTRDHCDOPNY-ZETCQYMHSA-N 0.000 description 1
- INNVYFUWDJOINA-UHFFFAOYSA-N tert-butyl 2-[[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]methyl]-5-fluoro-3-methylimidazole-4-carboxylate Chemical compound C(C)(C)(C)C=1C=C2C(=NNC2=CC1Cl)NCC=1N(C(=C(N1)F)C(=O)OC(C)(C)C)C INNVYFUWDJOINA-UHFFFAOYSA-N 0.000 description 1
- AYPWPGOPAZUJDF-UHFFFAOYSA-N tert-butyl n-(4,4-difluoropyrrolidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNCC1(F)F AYPWPGOPAZUJDF-UHFFFAOYSA-N 0.000 description 1
- VLOLOLUAVFGUTD-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate;hydron;chloride Chemical compound Cl.CC(C)(C)OC(=O)NC1CNC1 VLOLOLUAVFGUTD-UHFFFAOYSA-N 0.000 description 1
- BKITXDSDJGOXPN-SFYZADRCSA-N tert-butyl n-[(3r,4r)-4-methylpyrrolidin-3-yl]carbamate Chemical compound C[C@@H]1CNC[C@@H]1NC(=O)OC(C)(C)C BKITXDSDJGOXPN-SFYZADRCSA-N 0.000 description 1
- CGEBPOMWRHSMLI-QMMMGPOBSA-N tert-butyl n-[(7r)-5-azaspiro[2.4]heptan-7-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CNCC11CC1 CGEBPOMWRHSMLI-QMMMGPOBSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000006886 vinylation reaction Methods 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- the present application claims priority to Japanese Patent Application No. 2018-202226 filed on October 26, 2018 and Japanese Patent Application No. 2019-075118 filed on April 10, 2019 , which are incorporated herein by reference in their entirety.
- the present invention relates to an indazole compound having inhibitory activity against KRAS G12C mutation or a salt thereof, and relates to a pharmaceutical composition comprising this as an active ingredient.
- RAS which is a small monomeric GTP-binding protein having a molecular weight of about 21 kDa, acts as a molecular on/off switch.
- RAS can bind to GTP by binding to proteins of a guanine nucleotide exchange factor (GEF) (e.g., SOS1), which forces the release of a bound nucleotide, and releasing GDP.
- GEF guanine nucleotide exchange factor
- SOS1 guanine nucleotide exchange factor
- RAS binds to GTP, it becomes activated (turned on) and recruits and activates proteins necessary for the propagation of other receptors' signals, such as c-Raf and PI 3-kinase.
- RAS also possesses enzymatic activity with which it cleaves the terminal phosphate of the nucleotide and converts it to GDP. The rate of conversion is usually slow, but can be dramatically sped up by a protein of the GTPase-
- the mainly known members of the RAS subfamily include HRAS, KRAS, and NRAS.
- mutations of KRAS are observed in many malignant tumors: 95% of pancreatic cancers, 45% of colorectal cancers, and 35% of lung cancers.
- the mutations often occur in the glycine residue at position 12; in pulmonary adenocarcinoma, in particular, the mutation in the glycine residue at position 12 occurs in about 90% of the whole.
- the most often occurring mutation (44%) has been reported to be a mutation into cysteine (Non-patent Literature (NPL) 1).
- ARS-853 binds to the cysteine of the G12C mutant of inactive KRAS (GDP), thus preventing conversion of inactive KRAS (GDP) to active KRAS (GTP), inhibiting downstream signaling, and inducing apoptosis in cancer cells with KRAS G12C mutation (Patent Literature (PTL) 1 and NPL 2). It has also been reported that ARS-1620 with a quinazoline backbone exerts antitumor action in tumor-bearing mice expressing KRAS G12C mutation by improving metabolic stability of ARS-853 mice (PTL 2 and NPL 3).
- An object of the present invention is to provide a novel compound or a salt thereof that binds to the mutant cysteine of KRAS and inhibits downstream signaling, and to provide a pharmaceutical composition comprising this.
- the present inventors conducted extensive research to solve the above problems, and consequently found that the group of compounds represented by the following formula (I), containing indazole and heteroaryl, strongly binds to the cysteine of KRAS G12C mutant and inhibits functions of KRAS.
- the present invention has thus been accomplished.
- the present invention provides the following (1) to (43).
- An indazole compound represented by Formula (I) or a salt thereof impairs the KRAS function in KRAS G12C mutation-positive cancer cells, thereby showing antitumor action; therefore, an indazole compound represented by Formula (I) or a salt thereof can be used as an anti-cancer agent.
- the compound represented by Formula (I) above of the present invention contains indazole and a heteroaryl group in its basic structure, and is a novel compound that is nowhere disclosed in any of the literature cited above.
- CA-CB used in the description of a group indicates that the group has A to B number of carbon atoms.
- C1-C6 alkyl refers to alkyl having 1 to 6 carbon atoms
- C6-C14 aromatic hydrocarbon oxy refers to oxy to which C6-C14 aromatic hydrocarbon is bonded.
- A- to B-membered indicates that the number of atoms (number of ring members) that constitute a ring is A to B. More specifically, "4- to 10-membered saturated heterocyclic group” refers to a saturated heterocyclic group containing 4 to 10 ring members.
- C denotes a carbon atom
- N denotes a nitrogen atom
- S denotes a sulfur atom
- O denotes an oxygen atom
- H denotes a hydrogen atom.
- a double line denotes a double bond
- a double line one line of which is a dotted line, denotes a single bond or a double bond.
- examples of the "substituent" include hydrogen, halogen, cyano, nitro, amino, hydroxy, oxo, carbonyl, carboxy, carbamoyl, alkyl, haloalkyl, hydroxyalkyl, cyanoalkyl, cycloalkyl, cycloalkenyl, cycloalkyl-alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkoxy-alkyl, cycloalkoxy, cycloalkyl-alkoxy, cycloalkyl-haloalkyl, alkylthio, cycloalkyl-alkylthio, mono- or dialkylamino, alkylaminoalkyl, cycloalkyl-alkylamino, aromatic hydrocarbon, aralkyl, aralkyloxy, acyl, alkylcarbonyl, arylcarbonyl, acyl
- halogen examples include chlorine, bromine, fluorine, and iodine, with chlorine, fluorine, and bromine being preferable, and chlorine and fluorine being more preferable.
- alkyl refers to a linear or branched saturated hydrocarbon group.
- examples include C1-C10 alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, hexyl, and heptyl.
- alkyl is preferably C1-C6 alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl, and more preferably methyl, ethyl, or tert-butyl.
- haloalkyl refers to alkyl mentioned above having at least one halogen atom (preferably having 1 to 10, and more preferably 1 to 3 halogen atoms).
- Examples include C1-C6 haloalkyl, such as fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, 1-fluoroethyl, 1,1-difluoroethyl, 1,1,1-trifluoroethyl, 1-fluoro-n-propyl, 1,1,1-trifluoro-n-propyl, perfluoro-n-propyl, and perfluoroisopropyl, with trifluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl, and 1,1,1-trifluoroethyl being preferable.
- hydroxyalkyl refers to alkyl mentioned above having at least one hydroxy group (preferably having 1 to 10, and more preferably 1 to 2 hydroxy groups).
- examples include C1-C6 hydroxyalkyl, such as hydroxymethyl, hydroxyethyl, 1-hydroxypropyl, and 2-hydroxybutyl.
- cyanoalkyl refers to alky mentioned above having at least one cyano group (preferably having 1 to 10, and more preferably 1 to 2 cyano groups). Examples include C1-C6 cyanoalkyl, such as cyanomethyl, cyanoethyl, 1-cyanopropyl, and 2-cyanobutyl.
- cycloalkyl refers to monocyclic, bridged cyclic, or polycyclic saturated hydrocarbon.
- examples include C3-C10 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclodecyl, with cyclopropyl, cyclobutyl, and cyclopentyl being preferable, and cyclobutyl and cyclopentyl being particularly preferable.
- cycloalkenyl refers to monocyclic, bridged cyclic, or polycyclic unsaturated hydrocarbon containing at least one carbon-carbon double bond (e.g., one to two carbon-carbon double bonds, and preferably one carbon-carbon double bond).
- Examples include C4-C10 cycloalkenyl, such as cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclodecenyl, with cyclobutenyl, cyclopentenyl, and cyclohexenyl being preferable, and cyclobutenyl and cyclopentenyl being particularly preferable.
- cycloalkyl-alkyl refers to alkyl mentioned above having at least one cycloalkyl group.
- examples include C3-C10 cycloalkyl-C1-C4 alkyl, such as cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylisopropyl, cyclohexyl 1-methyl-4-isopropyl, and cycloheptylmethyl, with cyclohexylmethyl being preferable.
- the "unsaturated hydrocarbon” refers to linear or branched unsaturated hydrocarbon containing at least one carbon-carbon double bond or triple bond.
- examples include C2-C10 unsaturated hydrocarbon, such as vinyl, allyl, methylvinyl, 1-propenyl, butenyl, pentenyl, hexenyl, ethynyl, and 2-propynyl, with C2-6 linear or branched hydrocarbon containing at least one carbon-carbon double bond or triple bond being preferable, vinyl, allyl, and 1-propenyl being more preferable, and vinyl being most preferable.
- alkenyl refers to a linear or branched unsaturated hydrocarbon group containing at least one double bound (e.g., one to two double bonds, and preferably one double bond).
- Examples include C2-C10 alkenyl, such as vinyl, allyl, 1-propenyl, 2-methyl-2-propenyl, isopropenyl, 1-, 2-, or 3-butenyl, 2-, 3- or 4-pentenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, and 5-hexenyl, with C2-C6 alkenyl, such as vinyl, allyl, 1-propenyl, and 2-methyl-2-propenyl being preferable, and vinyl being most preferable.
- alkynyl refers to linear or branched unsaturated hydrocarbon containing at least one triple bond (e.g., one or two triple bonds, and preferably one triple bond).
- examples include C2-C10 alkynyl, such as ethynyl, 1- or 2-propynyl, 1-, 2-, or 3-butynyl, and 1-methyl-2-propynyl, with C2-C6 alkynyl, such as ethynyl and 2-propynyl, being preferable, and 2-propynyl being most preferable.
- alkoxy refers to oxy having alkyl mentioned above.
- examples include C1-C6 alkoxy, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, and hexyloxy, with methoxy and ethoxy being preferable, and methoxy being more preferable.
- haloalkoxy refers to alkoxy mentioned above having at least one halogen atom (preferably having 1 to 13, and more preferably 1 to 3 halogen atoms).
- examples include C1-C6 haloalkoxy, such as fluoromethoxy, difluoromethoxy, trifluoromethoxy, trichloromethoxy, fluoroethoxy, 1,1-difluoroethoxy, 1,1,1-trifluoroethoxy, monofluoro-n-propoxy, perfluoro-n-propoxy, and perfluoro-isopropoxy, with fluoroethoxy, difluoromethoxy, and trifluoromethoxy being preferable.
- alkoxy-alkyl refers to alkyl mentioned above having at least one alkoxy group mentioned above.
- examples include C1-C4 alkoxy-C1-C10 alkyl, such as methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, methoxypropyl, methoxy-n-, methoxypentyl, methoxyhexyl, methoxyheptyl, propoxyethyl, and butoxyethyl, with C1-C2 alkoxy-C1-C3 alkyl, such as methoxymethyl, ethoxymethyl, methoxyethyl, and ethoxyethyl being preferable, and methoxymethyl and methoxyethyl being more preferable.
- cycloalkoxy refers to oxy having cycloalkyl mentioned above.
- examples include C3-C10 cycloalkoxy, such as cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and cycloheptyloxy, with cyclobutoxy, cyclopentyloxy, and cyclohexyloxy being preferable.
- cycloalkyl-alkoxy refers to alkoxy mentioned above having at least one cycloalkyl group mentioned above.
- examples include C3-C10 cycloalkyl-C1-C4 alkoxy, such as cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, and cycloheptylmethoxy, with cyclohexylmethoxy being preferable.
- cycloalkyl-haloalkyl refers to haloalkyl mentioned above having at least one cycloalkyl group mentioned above.
- examples include C3-C10 cycloalkyl-C1-C4 haloalkyl, such as cyclopropylfluoromethyl, cyclobutylfluoromethyl, cyclopentylfluoromethyl, cyclohexylfluoromethyl, and cycloheptylfluoromethyl, with cyclohexylfluoromethyl being preferable.
- alkylthio refers to thioxy having alkyl mentioned above.
- Examples include C1-C6 alkylthio, such as methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio, n-pentylthio, isopentylthio, and hexylthio, with methylthio and ethylthio being preferable.
- cycloalkyl-alkylthio refers to alkylthio mentioned above having at least one cycloalkyl group mentioned above.
- examples include C3-C7 cycloalkyl-C1-C4 alkylthio, such as cyclopropylmethylthio, cyclobutylmethylthio, cyclopentylmethylthio, cyclohexylmethylthio, and cycloheptylmethylthio, with cyclohexylmethylthio being preferable.
- alkylamino refers to amino having one or two alkyl groups mentioned above. Specific examples include C1-C6 alkylamino, such as methylamino, ethylamino, dimethylamino, diethylamino, and ethylmethylamino, with methylamino, dimethylamino, and methylethylamino being preferable.
- the "monoalkylamino” refers to amino having one alkyl group mentioned above.
- Examples include C1-C6 monoalkylamino, such as methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, tert-butylamino, n-pentylamino, isopentylamino, and hexylamino, with methylamino being preferable.
- dialkylamino refers to amino having two alkyl groups mentioned above.
- examples include C2-C12 dialkylamino, such as dimethylamino, diethylamino, di(n-propyl)amino, diisopropylamino, di(n-butyl)amino, diisobutylamino, di(tert-butyl)amino, di(n-pentyl)amino, diisopentylamino, dihexylamino, methylethylamino, and methylisopropylamino, with dimethylamino being preferable.
- alkylaminoalkyl refers to alkyl mentioned above having at least one alkylamino group mentioned above.
- examples include C1-C6 alkylamino-C1-C6 alkyl, such as methylaminomethyl, methylaminoethyl, ethylaminomethyl, and ethylaminopropyl, with dimethylaminomethyl and dimethylaminoethyl being preferable.
- cycloalkyl-alkylamino refers to alkylamino mentioned above having cycloalkyl mentioned above in which cycloalkyl is attached to the alkyl moiety of alkylamino.
- examples include C3-C7 cycloalkyl-C1-C4 alkylamino, such as cyclopropylmethylamino, cyclobutylmethylamino, cyclopentylmethylamino, cyclohexylmethylamino, and cycloheptylmethylamino, with cyclobutylmethylamino and cyclohexylmethylamino being preferable.
- aromatic hydrocarbon refers to monocyclic or polycyclic aromatic hydrocarbon as being an unsaturated bond-containing ring substituent containing carbon and hydrogen, the monocyclic or polycyclic aromatic hydrocarbon containing 4e+2 number of electrons (e is an integer of 1 or more) in the cyclic ⁇ electron system.
- examples include phenyl, naphthyl, tetrahydronaphthyl, anthracenyl, and the like, with phenyl being preferable.
- aralkyl refers to alkyl mentioned above substituted with aromatic hydrocarbon mentioned above.
- examples include C7-C16 aralkyl, such as benzyl, phenylethyl, phenylpropyl, naphthylmethyl, and naphthylethyl, with benzyl being preferable.
- aralkyloxy refers to oxy having aralkyl mentioned above.
- examples include C7-C20 aralkyloxy, such as benzyloxy, phenethyloxy, naphthylmethyloxy, and fluorenylmethyloxy, with benzyloxy being preferable.
- acyl refers to carbonyl having alkyl mentioned above or aryl.
- Examples include substituted C1-C16 carbonyl, such as methylcarbonyl, ethylcarbonyl, and phenylcarbonyl, with methylcarbonyl and ethylcarbonyl being preferable.
- alkylcarbonyl refers to carbonyl having alkyl mentioned above, and is also included in the synonym "acyl.”
- Examples include C1-C6 alkylcarbonyl, such as methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, isobutylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl, isopentylcarbonyl, and hexylcarbonyl, with methylcarbonyl being preferable.
- C1-C6 alkylcarbonyl refers to (C1-C6 alkyl)carbonyl.
- arylcarbonyl refers to carbonyl having aromatic hydrocarbon mentioned above, and is also included in the synonym “acyl.”
- Examples include (C6-C20 aryl)carbonyl, such as phenylcarbonyl, naphthylcarbonyl, fluorenylcarbonyl, anthrylcarbonyl, biphenylylcarbonyl, tetrahydronaphthylcarbonyl, chromanylcarbonyl, 2,3-dihydro-1,4-dioxanaphthalenylcarbonyl, indanylcarbonyl, and phenanthrylcarbonyl.
- acyloxy refers to oxy having C1-C16 acyl mentioned above.
- the acyloxy is preferably oxy binding to substituted C1-C16 acyl, such as acetoxy, ethylacyloxy, and phenylacyloxy, and more preferably acetoxy, tert-butylcarbonyloxy, or phenylcarbonyloxy.
- alkylcarbonyloxy refers to oxy having alkylcarbonyl mentioned above, and is included in the synonym “acyloxy.”
- Examples include (C1-C6 alkyl)carbonyloxy, such as methylcarbonyloxy, ethylcarbonyloxy, n-propylcarbonyloxy, isopropylcarbonyloxy, n-butylcarbonyloxy, isobutylcarbonyloxy, tert-butylcarbonyloxy, n-pentylcarbonyloxy, isopentylcarbonyloxy, and hexylcarbonyloxy, with acetoxy and tert-butylcarbonyloxy being preferable.
- arylcarbonyloxy refers to oxy having arylcarbonyl mentioned above, and is included in the synonym “acyloxy.”
- Examples include (C6-C14 aryl)carbonyloxy, such as phenylcarbonyloxy, naphthylcarbonyloxy, fluorenylcarbonyloxy, anthrylcarbonyloxy, biphenylylcarbonyloxy, tetrahydronaphthylcarbonyloxy, chromanylcarbonyloxy, 2,3-dihydro-1,4-dioxanaphthalenylcarbonyloxy, indanylcarbonyloxy, and phenanthrylcarbonyloxy, with phenylcarbonyloxy being preferable.
- alkoxycarbonyl refers to carbonyl having alkoxy mentioned above.
- examples include (C1-C6 alkoxy)carbonyl, such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl, and hexyloxycarbonyl, with methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl being preferable, and tert-butoxycarbonyl being more preferable.
- aralkyloxycarbonyl refers to carbonyl having aralkyloxy mentioned above.
- examples include (C6-C20 aralkyl)oxycarbonyl, such as benzyloxycarbonyl, phenethyloxycarbonyl, naphthylmethyloxycarbonyl, and fluorenylmethyloxycarbonyl, with benzyloxycarbonyl being preferable.
- saturated heterocyclic group refers to a monocyclic or polycyclic saturated heterocyclic group containing at least one heteroatom (preferably having 1 to 5, and more preferably 1 to 3 heteroatoms) selected from nitrogen, oxygen, and sulfur.
- Examples include aziridinyl, azetidinyl, imidazolidinyl, morpholino, pyrrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, thiazolidinyl, thianyl, oxazolidinyl, morpholyl, and the like, with azetidinyl, pyrrolidinyl, and piperidinyl being preferable, and azetidinyl and pyrrolidinyl being more preferable.
- the "unsaturated heterocyclic group” refers to a monocyclic or polycyclic, completely or partially unsaturated heterocyclic group containing at least one heteroatom (preferably containing 1 to 5, and more preferably 1 to 3 heteroatoms) selected from nitrogen, oxygen, and sulfur.
- Examples include imidazolyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridyl, pyrazyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, indazolyl, triazolopyridyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, benzothienyl, furanyl, benzofuranyl, purinyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalyl, methylenedioxyphenyl, ethylenedioxyphenyl, dihydrobenzofuranyl, and the like, with imidazolyl, pyrazolyl, thiazo
- saturated heterocyclic oxy refers to oxy having a saturated heterocyclic group mentioned above.
- saturated heterocyclic group examples include morpholinyloxy, 1-pyrrolidinyloxy, piperidinooxy, piperazinyloxy, 4-methyl-1-piperazinyloxy, tetrahydrofuranyloxy, tetrahydropyranyloxy, tetrahydrothiophenyloxy, thiazolidinyloxy, oxazolidinyloxy, and the like, with azetidinyloxy and pyrrolidinyloxy being preferable.
- X represents nitrogen or CH, and preferably CH.
- R 1 represents hydrogen, halogen, cyano, nitro, amino, hydroxy, carboxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C10 cycloalkyl, C6-C10 aromatic hydrocarbon, a 4- to 10-membered saturated heterocyclic group, or a 5- to 10-membered unsaturated heterocyclic group.
- halogen represented by R 1 is preferably fluorine, chlorine, or bromine, and more preferably chlorine.
- C1-C6 alkyl in the "substituted or unsubstituted C1-C6 alkyl” represented by R 1 is preferably methyl, ethyl, n-propyl, or isopropyl (C1-C3 alkyl), more preferably methyl or ethyl, and particularly preferably methyl.
- the substituent in the "substituted or unsubstituted C1-C6 alkyl" represented by R 1 may be, for example, the substituents mentioned above, and is preferably, halogen, cyano, or hydroxy, and more preferably fluorine, chlorine, cyano, or hydroxy.
- the "substituted or unsubstituted C1-C6 alkyl" represented by R 1 is preferably C1-C6 alkyl, more preferably methyl, ethyl, or tert-butyl, more preferably methyl or ethyl, and particularly preferably methyl.
- C2-C6 alkenyl in the "substituted or unsubstituted C2-C6 alkenyl” represented by R 1 is preferably vinyl, 1-propenyl, allyl, or isopropenyl, and more preferably 1-propenyl.
- the substituent in the "substituted or unsubstituted C2-C6 alkenyl" represented by R 1 may be, for example, the substituents mentioned above, and is preferably halogen or hydroxy, and more preferably chlorine or fluorine.
- the "substituted or unsubstituted C2-C6 alkenyl" represented by R 1 is preferably 1-propenyl or 2-methyl-2-propenyl.
- C2-C6 alkynyl in the "substituted or unsubstituted C2-C6 alkynyl” represented by R 1 is preferably ethynyl or 1-propynyl.
- the substituent in the "substituted or unsubstituted C2-C6 alkynyl" represented by R 1 may be, for example, the substituents mentioned above, and is preferably halogen or hydroxy, and more preferably fluorine or chlorine.
- the "substituted or unsubstituted C2-C6 alkynyl" represented by R 1 is preferably C2-C6 alkynyl, and more preferably ethynyl or 1-propynyl.
- C3-C10 cycloalkyl in the "substituted or unsubstituted C3-C10 cycloalkyl” represented by R 1 is preferably cyclobutyl, cyclopentyl, or cyclohexyl.
- the substituent in the "substituted or unsubstituted C3-C10 cycloalkyl" represented by R 1 may be, for example, the substituents mentioned above, and is preferably halogen or C1-C6 alkyl, and more preferably methyl, ethyl, n-propyl, fluorine, or chlorine.
- the "substituted or unsubstituted C3-C10 cycloalkyl" represented by R 1 is preferably C3-C10 cycloalkyl, and more preferably cyclobutyl, cyclopentyl, or cyclohexyl.
- the "C6-C10 aromatic hydrocarbon” represented by R 1 is preferably phenyl.
- the "4- to 10-membered saturated heterocyclic group" represented by R 1 is preferably a monocyclic or bicyclic 4- to 10-membered saturated heterocyclic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur, more preferably a monocyclic 4- to 7-membered saturated heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and more preferably aziridinyl, pyrrolidinyl, or piperidinyl.
- the "5- to 10-membered unsaturated heterocyclic group" represented by R 1 is preferably a monocyclic or bicyclic 5- to 10-membered unsaturated heterocyclic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur, more preferably a monocyclic 5- to 7-membered unsaturated heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and more preferably pyridyl.
- R 1 is preferably hydrogen, halogen, or a substituted or unsubstituted C1-C6 alkyl.
- R 1 is more preferably hydrogen, halogen, or C1-C6 alkyl.
- R 1 is more preferably halogen or C1-C6 alkyl.
- R 1 is more preferably halogen or methyl.
- R 1 is more preferably chlorine or methyl.
- R 1 is most preferably chlorine.
- R 2 represents hydrogen, cyano, nitro, amino, hydroxy, carboxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C10 cycloalkyl, C6-C10 aromatic hydrocarbon, a 4- to 10-membered saturated heterocyclic group, or a 5- to 10-membered unsaturated heterocyclic group.
- the "C1-C6 alkyl" in the "substituted or unsubstituted C1-C6 alkyl” represented by R 2 is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, or n-pentyl, more preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, or tert-butyl, more preferably methyl, ethyl, or tert-butyl, and most preferably tert-butyl.
- the substituent in the "substituted or unsubstituted C1-C6 alkyl" represented by R 2 may be, for example, the substituents mentioned above, and is preferably halogen, cyano, hydroxy, or C3-C7 cycloalkyl, and more preferably fluorine, chlorine, cyclopropyl, or cyclobutyl.
- the "substituted or unsubstituted C1-C6 alkyl" represented by R 2 is preferably C1-C6 alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, and n-pentyl, more preferably methyl, ethyl, isopropyl, and tert-butyl, still more preferably isopropyl or tert-butyl, and most preferably tert-butyl.
- C1-C6 alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, and n-pentyl, more preferably methyl, ethyl, isopropyl, and tert-butyl, still
- C2-C6 alkenyl in the "substituted or unsubstituted C2-C6 alkenyl” represented by R 2 is preferably vinyl, 1-propenyl, allyl, or isopropenyl, and more preferably vinyl or isopropenyl.
- the substituent in the "substituted or unsubstituted C2-C6 alkenyl" represented by R 2 may be, for example, the substituents mentioned above, and is preferably halogen, cyano, or hydroxy, more preferably chlorine or fluorine, and more preferably fluorine.
- the "substituted or unsubstituted C2-C6 alkenyl" represented by R 2 is preferably C2-C6 alkenyl that may contain halogen, more preferably vinyl, 1-propenyl, 2-methyl-2-propenyl, or 1-(trifluoromethyl)vinyl, and more preferably vinyl or 1-(trifluoromethyl)vinyl.
- C2-C6 alkynyl in the "substituted or unsubstituted C2-C6 alkynyl” represented by R 2 is preferably ethynyl or 1-propynyl.
- the substituent in the "substituted or unsubstituted C2-C6 alkynyl" represented by R 2 may be, for example, the substituents mentioned above, and is preferably halogen or hydroxy, more preferably fluorine or chlorine, and still more preferably fluorine.
- the "substituted or unsubstituted C2-C6 alkynyl" represented by R 2 is preferably ethynyl or 1-propynyl.
- C3-C10 cycloalkyl in the "substituted or unsubstituted C3-C10 cycloalkyl” represented by R 2 is preferably cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and more preferably cyclopropyl.
- the substituent in the "substituted or unsubstituted C3-C10 cycloalkyl" represented by R 2 may be, for example, the substituents mentioned above, and is preferably halogen, C1-C6 alkyl, or C1-C6 haloalkyl, more preferably fluorine, chlorine, methyl, ethyl, n-propyl, fluoromethyl, difluoromethyl, or trifluoromethyl, and still more preferably fluorine, methyl, ethyl, or trifluoromethyl.
- the "substituted or unsubstituted C3-C10 cycloalkyl" represented by R 2 is preferably C3-C10 cycloalkyl that may contain C1-C6 haloalkyl, and more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 1-(trifluoromethyl)cyclopropyl.
- the "C6-C10 aromatic hydrocarbon” represented by R 2 is preferably phenyl.
- the "4- to 10-membered saturated heterocyclic group" represented by R 2 is preferably a monocyclic or bicyclic 4- to 10-membered saturated heterocyclic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur, and more preferably a monocyclic 4- to 7-membered saturated heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and more preferably aziridinyl, pyrrolidinyl, piperidinyl, or tetrahydropyranyl.
- the "5- to 10-membered unsaturated heterocyclic group" represented by R 2 is preferably a monocyclic or bicyclic 5- to 10-membered unsaturated heterocyclic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur, more preferably a monocyclic 5- to 7-membered unsaturated heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and more preferably pyridyl.
- R 2 is preferably substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, or substituted or unsubstituted C3-C10 cycloalkyl.
- R 2 is more preferably C1-C6 alkyl, C2-C6 alkenyl that may contain halogen, or C3-C10 cycloalkyl that may contain C1-C6 haloalkyl.
- R 2 is more preferably C1-C6 alkyl, vinyl, 1-(trifluoromethyl)vinyl, or 1-(trifluoromethyl)cyclopropyl.
- R 2 is more preferably C1-C6 alkyl.
- R 2 is more preferably C3-C6 alkyl.
- R 2 is most preferably tert-butyl.
- Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or C1-C6 alkyl.
- the "C1-C6 alkyl” represented by Ra is preferably methyl or ethyl, and most preferably methyl.
- Ra is preferably a hydrogen atom, a deuterium atom, or methyl, and most preferably a hydrogen atom.
- L 1 repesents -NH-C(Ra) 2 -.
- L 1 preferably represents -NH-C(Ra) 2 , wherein one of the two Ras is a hydrogen atom while the other is a hydrogen atom, a deuterium atom, or methyl, and most preferably -NH-CH 2 -.
- ring A represents a substituted or unsubstituted 5-membered unsaturated heterocyclic group.
- Ring A typically represents a substituted or unsubstituted 5-membered unsaturated heterocyclic group containing two double bonds in the ring.
- A1, A2, and A3 are identical or different, and represent substituted or unsubstituted carbon, substituted or unsubstituted nitrogen, sulfur, or oxygen
- one of A1, A2, and A3 represents substituted or unsubstituted nitrogen or sulfur
- two of the rest of A1, A2, and A3 are identical or different, and represent substituted or unsubstituted carbon, substituted or unsubstituted nitrogen, sulfur, or oxygen.
- Ring A is preferably a substituted or unsubstituted group in which two hydrogen atoms are removed from imidazole, pyrazole, thiazole, or oxazol, more preferably a substituted or unsubstituted group in which two hydrogen atoms are removed from imidazole, pyrazole, or thiazole, and most preferably a substituted or unsubstituted group in which two hydrogen atoms are removed from imidazole.
- the "5-membered unsaturated heterocyclic group" represented by ring A is preferably a group in which two hydrogen atoms are removed from imidazole, pyrazole, thiazole, or oxazol, more preferably a substituted or unsubstituted group in which two hydrogen atoms are removed from imidazole, pyrazole, or thiazole, and most preferably a group in which two hydrogen atoms are removed from imidazole.
- the substituent in the "substituted or unsubstituted 5-membered unsaturated heterocyclic group" represented by ring A may be, for example, the substituents mentioned above, and is preferably hydrogen, halogen, cyano, nitro, amino, hydroxy, carboxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C4-C10 cycloalkenyl, substituted or unsubstituted C6-C10 aromatic hydrocarbon, a substituted or unsubstituted 4- to 10- membered saturated heterocyclic group, or a substituted or unsubstituted 5- to 10-membered unsaturated heterocyclic group.
- halogen included in the substituents of ring A is preferably fluorine or chlorine.
- C1-C6 alkyl in the "substituted or unsubstituted C1-C6 alkyl” included in the substituents of ring A is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl, or n-pentyl, and more preferably methyl or ethyl.
- the substituent in the "substituted or unsubstituted C1-C6 alkyl" included in the substituents of ring A may be, for example, the substituents mentioned above, and is preferably halogen, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-C6 alkylamino, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C10 aromatic hydrocarbon, or a substituted or unsubstituted 4- to 10-membered saturated heterocyclic group, more preferably halogen, C1-C6 alkoxy, C1-C6 alkylamino, C3-C10 cycloalkyl that may contain C1-C6 alkoxy, C6-C10 aromatic hydrocarbon, or a 4- to 10-membered saturated heterocyclic group that may contain C1-C6 alkyl, and more preferably halogen, C1
- the "substituted or unsubstituted C1-C6 alkyl" included in the substituents of ring A is preferably C1-C6 alkyl substituted or unsubstituted with at least one substituent selected from the group consisting of halogen, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-C6 alkylamino, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C10 aromatic hydrocarbon, and a substituted or unsubstituted 4- to 10-membered saturated heterocyclic group, more preferably C1-C6 alkyl substituted or unsubstituted with at least one substituent selected from the group consisting of halogen, C1-C6 alkoxy, C1-C6 alkylamino, C3-C10 cycloalkyl that may contain C1-C6 alkoxy, C6-
- C2-C6 alkenyl in the "substituted or unsubstituted C2-C6 alkenyl” included in the substituents of ring A is preferably vinyl or allyl.
- the substituent in the "substituted or unsubstituted C2-C6 alkenyl" included in the substituents of ring A may be, for example, the substituents mentioned above, and is preferably halogen, and more preferably fluorine or chlorine.
- the "substituted or unsubstituted C2-C6 alkenyl" included in the substituents of ring A is preferably vinyl or allyl.
- C2-C6 alkynyl in the "substituted or unsubstituted C2-C6 alkynyl” included in the substituents of ring A is preferably ethynyl or 1-propynyl.
- the substituent in the "substituted or unsubstituted C2-C6 alkynyl" included in the substituents of ring A may be, for example, the substituents mentioned above, and is preferably halogen, and more preferably fluorine or chlorine.
- the "substituted or unsubstituted C2-C6 alkynyl" included in the substituents of ring A is preferably ethynyl or 1-propynyl.
- C3-C10 cycloalkyl in the "substituted or unsubstituted C3-C10 cycloalkyl” included in the substituents of ring A include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclodecyl, and the like, with C3-C7 cycloalkyl being preferable, and cyclopropyl, cyclopentyl, and cyclohexyl being more preferable.
- the substituent in the "substituted or unsubstituted C3-C10 cycloalkyl" included in the substituents of ring A may be, for example, the substituents mentioned above, and is preferably hydroxy, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C1-C6 alkoxy, more preferably hydroxy, C1-C6 alkyl, or C1-C6 alkoxy, and more preferably hydroxy, methyl, isopropyl, or methoxy.
- the "substituted or unsubstituted C3-C10 cycloalkyl" included in the substituents of ring A is preferably C3-C10 cycloalkyl substituted or unsubstituted with a substituent selected from the group consisting of hydroxy, substituted or unsubstituted C1-C6 alkyl, and substituted or unsubstituted C1-C6 alkoxy, more preferably C3-C10 cycloalkyl substituted or unsubstituted with a substituent selected from the group consisting of hydroxy, C1-C6 alkyl, and C1-C6 alkoxy, more preferably C3-C7 cycloalkyl substituted or unsubstituted with a substituent selected from the group consisting of hydroxy, C1-C6 alkyl, and C1-C6 alkoxy, and more preferably cyclopropyl, cyclopentyl, cyclohexyl, 3,4-
- C4-C10 cycloalkenyl in the "substituted or unsubstituted C4-C10 cycloalkenyl” included in the substituents of ring A include cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclodecenyl, and the like, with C4-C7 cycloalkenyl being preferable, and cyclopentenyl being more preferable.
- the substituent in the "substituted or unsubstituted C4-C10 cycloalkenyl" included in the substituents of ring A may be, for example, the substituents mentioned above, and is preferably halogen, and more preferably fluorine or chlorine.
- the "substituted or unsubstituted C4-C10 cycloalkenyl" included in the substituents of ring A is preferably C4-C10 cycloalkenyl, more preferably C4-C7 cycloalkenyl, and more preferably cyclopentenyl.
- C6-C10 aromatic hydrocarbon in the "substituted or unsubstituted C6-C10 aromatic hydrocarbon” included in the substituents of ring A is preferably phenyl, naphthyl, or tetrahydronaphthyl, and more preferably phenyl.
- the substituent in the "substituted or unsubstituted C6-C10 aromatic hydrocarbon" included in the substituents of ring A may be, for example, the substituents mentioned above, and is preferably halogen, and more preferably fluorine or chlorine.
- the "substituted or unsubstituted C6-C10 aromatic hydrocarbon” included in the substituents of ring A is preferably C6-C10 aromatic hydrocarbon, and more preferably phenyl.
- the "4- to 10-membered saturated heterocyclic group" in the "substituted or unsubstituted 4- to 10-membered saturated heterocyclic group” included in the substituents of ring A is preferably a monocyclic or bicyclic 4- to 10-membered saturated heterocyclic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur, more preferably a monocyclic 4- to 7-membered saturated heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and more preferably azetidinyl, pyrrolidinyl, or piperidinyl.
- the "substituent" in the "substituted or unsubstituted 4- to 10-membered saturated heterocyclic group” included in the substituents of ring A may be, for example, the substituents mentioned above, and is preferably substituted or unsubstituted C1-C6 alkyl, C1-C6 alkenyl, (C1-C6 alkyl)carbonyl, (C1-C6 alkoxy)carbonyl, C3-C10 cycloalkyl, C6-C10 aromatic hydrocarbon, a 4- to 10-membered saturated heterocyclic group, or a 5- to 10-membered unsaturated heterocyclic group, more preferably C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy-C1-C6 alkyl, C7-C16 aralkyl, C1-C6 alkenyl, (C1-C6 alkyl)carbonyl, (C1-C6 al
- the "substituted or unsubstituted 4- to 10-membered saturated heterocyclic group" included in the substituents of ring A is preferably N-tert-butoxycarbonylazetidinyl, N-isopropylazetidinyl, N-acetylazetidinyl, N-methylpyrrolidinyl, N-ethylpyrrolidinyl, N-acetylpyrrolidinyl, N-isopropylpyrrolidinyl, N-pyridinepyrrolidinyl, N-2-methoxyethyl-pyrrolidinyl, N-cyclopropylpyrrolidinyl, N-oxetanylpyrrolidinyl, N-benzylpyrrolidinyl, N-carboxylateazetidinyl, N-difluoroethyl-pyrrolidinyl, N-prop-2-enyl-pyrrolidinyl, 1-(
- the "5- to 10-membered unsaturated heterocyclic group" included in the substituents of ring A is preferably pyridinyl.
- the substituent in the "substituted or unsubstituted 5-to 10-membered unsaturated heterocyclic group" included in the substituent of ring A may be, for example, the substituents mentioned above, and is preferably halogen, hydroxy, or C1-C6 alkyl, and more preferably methyl, ethyl, hydroxy, fluorine, or chlorine.
- the "substituted or unsubstituted 5- to 10-membered unsaturated heterocyclic group" in the “substituted or unsubstituted 5- to 10-membered unsaturated heterocyclic group” included in the substituents of ring A is preferably a 5- to 10-membered unsaturated heterocyclic group, and more preferably pyridinyl or N-methylpyridinyl.
- L 2 represents wherein represent a 4- to 8-membered saturated heterocyclic group that may contain 1 or 2 heteroatoms selected from sulfur and oxygen, and that contains at least one, and preferably 1 or 2, nitrogen atoms, and
- L 2 preferably represents a 4- to 8-membered saturated heterocyclic group that does not contain sulfur or oxygen, and contains at least one nitrogen atom (preferably one or two nitrogen atoms), and more preferably, azetidinyl, pyrrolidinyl, or piperidinyl.
- L 2 preferably represents a 4- to 8-membered saturated heterocyclic group that does not contain sulfur or oxygen, and contains at least one nitrogen atom (preferably one or two nitrogen atoms), and more preferably azetidinyl, pyrrolidinyl, or piperidinyl.
- L 2 preferably represents a 4- to 8-membered saturated heterocyclic group that does not contain sulfur or oxygen, and contains at least two (preferably two or three) nitrogen atoms, and more preferably 1,3-diazetidinyl, imidazolidinyl, or piperazinyl.
- the "C1-C6 alkyl" represented by R 3 is preferably methyl or ethyl, and more preferably methyl.
- the "halogen" represented by R 4 is preferably fluorine.
- the "C1-C6 alkyl" represented by R 4 is preferably methyl or ethyl.
- the "C2-C6 alkenyl” represented by R 4 is preferably vinyl or allyl.
- the "C2-C6 alkynyl” represented by R 4 is preferably ethynyl.
- the "C1-C6 alkoxy" represented by R 4 is preferably methoxy.
- the "C1-C6 haloalkyl" represented by R 4 is preferably fluoromethyl.
- the "C1-C6 cyanoalkyl" represented by R 4 is preferably cyanomethyl.
- C1-C6 alkylamino-C1-C6 alkyl represented by R 4 is preferably N,N-dimethylaminomethyl.
- C1-C6 alkoxy-C1-C6 alkyl represented by R 4 is preferably methoxymethyl or methoxyethyl, and more preferably methoxymethyl.
- the "C1-C6 hydroxyalkyl" represented by R 4 is preferably hydroxymethyl or 2-hydroxyethyl, and more preferably hydroxymethyl.
- R 4 s When two R 4 s are attached to the same carbon atom, and these two R 4 s each represent C1-C6 alkyl, these two R 4 s, taken together with the carbon atom to which these groups are attached, may form a ring.
- Such a ring has a structure in which, for example, two hydrogen atoms that attach to the same carbon are removed from C3-C6 (preferably C3-C4, and more preferably C3) cycloalkane.
- n 0, 1, 2, or 3. n is preferably 0, 1, or 2, more preferably 0 or 1, and most preferably 0.
- L 2 above represent a 4- to 6-membered saturated heterocyclic group containing 1 or 2 nitrogen atoms
- R 3 represents hydrogen or methyl
- R 4 represents halogen, cyano, cyanomethyl, hydroxy, C1-C2 alkyl, methoxy, C1-C2 haloalkyl, C1-C2 hydroxyalkyl, dimethylaminomethyl, methoxymethyl, or ethoxymethyl.
- these two R 4 s when two R 4 s are attached to the same carbon atom, and these two R 4 s each represent C1-C2 alkyl, these two R 4 s, taken together with the carbon atom to which these groups are attached, may form a structure in which two hydrogen atoms that attach to the same carbon are removed from C3-C5 (preferably C3) cycloalkane.
- L 2 represents wherein
- R 5 represents substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl.
- the compound or a salt thereof according to the present invention has structural features as represented by Formula (I) above; in particular, due to the above structure of R 5 , the compound or a salt thereof according to the present invention can specifically bind to the cysteine residue of the G12C mutant of KRAS.
- C2-C6 alkenyl in the "substituted or unsubstituted C2-C6 alkenyl” represented by R 5 is preferably vinyl, 1-propenyl, allyl, or isopropenyl.
- the "substituent" in the "substituted or unsubstituted C2-C6 alkenyl” represented by R 5 may be, for example, the substituents mentioned above, and is preferably halogen, C1-C6 alkylamino, C1-C6 alkoxy, or a 4- to 10-membered saturated heterocyclic group, and more preferably chlorine, methoxymethyl, dimethylamino, or piperidinyl.
- the "substituted or unsubstituted C2-C6 alkenyl" represented by R 5 is preferably vinyl, 1-propenyl, 1-chlorovinyl, 2-chlorovinyl, 3-(dimethylamino)prop-1-en-1-yl, 3-(piperidin-1-yl)prop-1-en-1-yl, or 3-(methoxy)prop-1-en-1-yl.
- C2-C6 alkynyl in the "substituted or unsubstituted C2-C6 alkynyl” represented by R 5 is preferably ethynyl, 1-propynyl, or 2-propynyl.
- the substituent in the "substituted or unsubstituted C2-C6 alkynyl" represented by R 5 may be, for example, the substituents mentioned above, and is preferably halogen, C1-C6 alkyl, or C1-C6 alkoxy, and more preferably fluorine, chlorine, methyl, or methoxy.
- the "substituted or unsubstituted C2-C6 alkynyl" represented by R 5 is preferably ethynyl.
- R 5 is preferably substituted or unsubstituted C2-C6 alkenyl, more preferably substituted or unsubstituted C2-C3 alkenyl, and most preferably vinyl.
- R 5 is preferably substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl (the substituent is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkylamino, C1-C6 alkoxy, and 4- to 10-membered saturated heterocyclic group), more preferably substituted or unsubstituted C2-C6 alkenyl (the substituent is selected from the group consisting of halogen, C1-C6 alkylamino, C1-C6 alkoxy, and 4- to 10-membered saturated heterocyclic group) or substituted or unsubstituted C2-C6 alkynyl (the substituent is selected from halogen, C1-C6 alkyl, and C1-C6 alkoxy), more preferably substituted or unsubstituted C2-C3 alkenyl (the substituent is selected from the group consisting of chlorine, methoxy
- the alkyl when ring A is substituted with alkyl, the alkyl is preferably not substituted with C6-C10 aromatic hydrocarbon, a 4- to 10-membered saturated heterocyclic group, or a 5- to 10-membered unsaturated heterocyclic group.
- the substituent is at least one member selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, carboxy, C1-C6 alkyl that may have Rb, C2-C6 alkenyl that may have Rb, C2-C6 alkynyl that may have Rb, C3-C10 cycloalkyl that may have Rc, C3-C10 cycloalkenyl that may have Rc, C6-C10 aromatic hydrocarbon that may have Rc, a 4- to 10-membered saturated heterocyclic group that may have Rc, and a 4-to 10-membered unsaturated heterocyclic group that may have Rc.
- Rb represents halogen, cyano, nitro, amino, hydroxy, carboxy, C1-C6 alkoxy, C1-C6 alkylamino, C3-C6 cycloalkyl, substituted or unsubstituted C6-C10 aromatic hydrocarbon, or a substituted or unsubstituted 4- to 10-membered saturated heterocyclic group
- Rc represents halogen, cyano, nitro, amino, hydroxy, carboxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 alkylcarbonyl, C1-C6 alkoxy-C1-C6 alkyl, C7-C20 aralkyl, C1-C6 alkoxycarbonyl, C3-C6 cycloalkyl, C6-C10 aromatic hydro
- Rb is preferably halogen, C1-C6 alkoxy, C1-C6 alkylamino, C3-C10 cycloalkyl, substituted or unsubstituted C6-C10 aromatic hydrocarbon, or a substituted or unsubstituted 4- to 10-membered saturated heterocyclic group.
- Rb is more preferably halogen, C1-C3 alkoxy, C1-C3 alkylamino, C3-C6 cycloalkyl, substituted or unsubstituted phenyl, or a substituted or unsubstituted 4- to 5-membered saturated heterocyclic group.
- Rb is more preferably chlorine, fluorine, methoxy, cyclopentyl, phenyl, 2,4-dimethoxyphenyl, dimethylamino, or N-isopropyl-pyrrolidinyl.
- Rb is more preferably chlorine, methyl, ethyl, cyano, difluoromethyl, trifluoromethyl, or 2,4-dimethoxyphenyl.
- Rc is preferably halogen, hydroxy, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 alkylcarbonyl, C1-C6 alkoxy-C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxycarbonyl, C7-C20 aralkyl, a 4- to 10- membered saturated heterocyclic group, or a 5- to 10-membered unsaturated heterocyclic group.
- Rc is more preferably halogen, hydroxy, C1-C3 alkyl, C2-C3 alkenyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 alkylamino, C1-C3 alkylcarbonyl, C1-C3 alkoxy C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxycarbonyl, benzyl, a 4- to 6-membered saturated heterocyclic group, or a 5- to 6-membered unsaturated heterocyclic group.
- Rc is still more preferably chlorine, fluorine, hydroxy, methyl, ethyl, isopropyl, acetyl, methoxy, vinyl, difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, cyclopropyl, oxetanyl, benzyl, tert-butoxycarbonyl, methoxyethyl, or pyridinyl.
- A1 preferably represents substituted carbon or substituted nitrogen, and the substituent is preferably hydrogen, cyano, halogen, C1-C6 alkyl that may have Rb, C2-C6 alkenyl that may have Rb, C3-C10 cycloalkyl that may have Rc, C4-C10 cycloalkenyl that may have Rc, a 4- to 10- membered saturated heterocyclic group that may have Rc, or a 4- to 10- membered unsaturated heterocyclic group that may have Rc.
- A1 more preferably represents substituted nitrogen, and the substituent is hydrogen, halogen, C1-C6 alkyl (substituted or unsubstituted with a substituent selected from the group consisting of halogen, C1-C6 alkoxy, C1-C6 alkylamino, C3-C10 cycloalkyl, substituted or unsubstituted C6-C10 aromatic hydrocarbon, and a substituted or unsubstituted, 4- to 10-membered saturated heterocyclic group), C3-C10 cycloalkyl (substituted or unsubstituted with a substituent selected from the group consisting of hydroxy, C1-C6 alkyl, and C1-C6 alkoxy), C3-C10 cycloalkenyl, a 4- to 10- membered saturated heterocyclic group (substituted or unsubstituted with a substituent selected from the group consisting of C1-C6 alkyl, C1-
- A1 more preferably represents substituted nitrogen, and the substituent is hydrogen, halogen, C1-C6 alkyl (substituted or unsubstituted with a substituent selected from the group consisting of halogen, C1-C3 alkoxy, C1-C3 alkylamino, C3-C6 cycloalkyl, substituted or unsubstituted phenyl, and a substituted or unsubstituted 4- to 5-membered saturated heterocyclic group), C3-C6 cycloalkyl (substituted or unsubstituted with a substituent selected from the group consisting of hydroxy, C1-C3 alkyl, and C1-C3 alkoxy), C3-C6 cycloalkenyl, a 4- to 5-membered saturated heterocyclic group (substituted or unsubstituted with a substituent selected from the group consisting of C1-C3 alkyl, C1-C3 halo
- A1 still more preferably represents substituted nitrogen, and the substituent is hydrogen, chlorine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclopentyl, 3,4-dihydroxycyclopentyl, cyclohexyl, 2-isopropyl-5-methylcyclohexyl, 4-methoxycyclohexyl, cyclopentenyl, N-tert-butoxycarbonylaziridinyl, N-isopropylaziridinyl, N-methylcarbonylaziridinyl, N-methylpyrrolidinyl, N-ethylpyrrolidinyl, N-isopropylpyrrolidinyl, N-(2,2-difluoroethyl)pyrrolidinyl, N-methylcarbonylpyrrolidinyl, N-methoxyethylpyr
- A1 still more preferably represents substituted nitrogen, and the substituent is hydrogen, chlorine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopentyl, 4-methoxycyclohexyl, N-isopropylaziridinyl, N-methylpyrrolidinyl, N-isopropylpyrrolidinyl, N-(2,2-difluoroethyl)pyrrolidinyl, N-(2,2-difluoroethyl)piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl.
- A2 preferably represents sulfur or substituted nitrogen, and the substituent is hydrogen, halogen, cyano, nitro, amino, hydroxy, carboxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, or substituted or unsubstituted C2-C6 alkynyl.
- A2 still more preferably represents substituted nitrogen, and the substituent is hydrogen, halogen, cyano, hydroxy, or C1-C6 alkyl.
- A2 still more preferably represents substituted nitrogen, and the substituent is hydrogen, methyl, or ethyl.
- the substituent of A2 is most preferably nitrogen that is substituted with hydrogen.
- A3 preferably represens substituted carbon or substituted nitrogen, and the substituent is hydrogen, halogen, cyano, nitro, amino, hydroxy, carboxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, or substituted or unsubstituted C2-C6 alkynyl.
- A3 more preferably represens substituted carbon or substituted nitrogen, and the substituent is hydrogen, halogen, cyano, nitro, amino, hydroxy, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, or C2-C6 alkynyl.
- A3 still more preferably represents substituted carbon, and the substituent is hydrogen, halogen, cyano, C1-C6 alkyl, or C1-C6 haloalkyl.
- A3 most preferably represents substituted carbon, and the substituent is methyl, ethyl, difluoromethyl, chlorine, fluorine, or cyano.
- a preferable combination of A1, A2, and A3 is a combination of A1 being substituted nitrogen, A2 being nitrogen, and A3 being substituted carbon; a combination of A1 being nitrogen, A2 being sulfur, and A3 being substituted carbon; a combination of A1 being substituted carbon, A2 being nitrogen, and A3 being substituted nitrogen; or a combination of A1 being sulfur, A2 being nitrogen, and A3 being substituted carbon.
- a more preferable combination of A1, A2, and A3 is a combination of A1 being substituted nitrogen, A2 being nitrogen, and A3 being substituted carbon; or a combination of A1 being nitrogen, A2 being sulfur, and A3 being substituted carbon.
- a most preferable combination of A1, A2, and A3 is a combination of A1 being substituted nitrogen, A2 being nitrogen, and A3 being substituted carbon.
- the compound or a salt thereof of the present invention is preferably a compound represented by Formula (I) or a salt thereof, wherein X represents nitrogen or CH, R 1 represents hydrogen, halogen, cyano, nitro, amino, hydroxy, carboxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C10 cycloalkyl, C6-C10 aromatic hydrocarbon, a 4- to 10-membered saturated heterocyclic group, or a 5- to 10-membered unsaturated heterocyclic group, L 1 represents -NH-C(Ra) 2 -, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or C1-C6 alkyl, ring A represents a substituted or unsubstituted, 5-membered unsaturated heterocycl
- the compound or a salt thereof of the present invention is more preferably a compound represented by Formula (I) or a salt thereof, wherein X represents N or CH, R 1 represents halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, or substituted or unsubstituted C3-C10 cycloalkyl, L 1 represents -NH-C(Ra) 2 -, and one of the two Ras is a hydrogen atom while the other is a hydrogen atom, a deuterium atom, or methyl, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or methyl, ring A is a combination of A1, A2, and A3, wherein A1 is substituted nitrogen, A2 is nitrogen, and A3 is substituted carbon; A1 is substituted nitrogen, A2 is sulfur, and A3 is substituted carbon; A1 is substituted carbon, A2 is nitrogen, and A
- the compound or a salt thereof of the present invention is still more preferably a compound represented by Formula (I) or a salt thereof, wherein X represents CH, R 1 represents halogen, substituted or unsubstituted C1-C3 alkyl, 1-propenyl, 2-methyl-2-propenyl, or 1-methylcyclopropyl, L 1 represents -NH-C(Ra) 2 -, and one of the two Ras is a hydrogen atom while the other is a hydrogen atom, a deuterium atom, or methyl, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or methyl, ring A is a combination of A1, A2, and A3, wherein A1 is substituted nitrogen, A2 is nitrogen, and A3 is substituted carbon; or A1 is substituted nitrogen, A2 is sulfur, and A3 is substituted carbon; the substituent of A1 is hydrogen, halogen, C1-C6 alkyl (substituted or unsub
- the compound or a salt thereof of the present invention is still more preferably a compound represented by Formula (I) or a salt thereof, wherein X represents CH, R 1 represents chlorine or substituted C1-C3 alkyl, L 1 represents -NH-CH 2 -, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or methyl, ring A is a combination of A1, A2, and A3, wherein A1 is substituted nitrogen, A2 is nitrogen, and A3 is substituted carbon; or A1 is nitrogen, A2 is sulfur, and A3 is substituted carbon, the substituent of A1 is hydrogen, chlorine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclopentyl, 3,4-dihydroxycyclopentyl, cyclohexyl, 2-isopropyl-5-methylcyclohexyl
- the compound or a salt thereof of the present invention is most preferably a compound represented by Formula (I) or a salt thereof, wherein X represents CH, R 1 represents chlorine or tert-butyl, L 1 represents -NH-CH 2 -, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or methyl, ring A is a combination of A1, A2, and A3, wherein A1 is substituted nitrogen, A2 is nitrogen, and A3 is substituted carbon, the substituent of A1 is hydrogen, chlorine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopentyl, 4-methoxycyclohexyl, N-isopropylaziridinyl, N-methylpyrrolidinyl, N-isopropylpyrrolidinyl, N-(2,2-difluoroethyl)pyrrol
- the compound or a salt thereof of the present invention is preferably a compound represented by Formula (I) or a salt thereof, wherein X represents nitrogen or CH, R 1 represents hydrogen, halogen, cyano, nitro, amino, hydroxy, carboxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C10 cycloalkyl, C6-C10 aromatic hydrocarbon, a 4- to 10-membered saturated heterocyclic group, or a 5- to 10-membered unsaturated heterocyclic group, L 1 represents -NH-C(Ra) 2 -, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or C1-C6 alkyl, ring A represents a substituted or unsubstituted, 5-membered unsaturated heterocycl
- the compound or a salt thereof of the present invention is more preferably a compound represented by Formula (I) or a salt thereof, wherein X represents CH, R 1 represents halogen, substituted or unsubstituted C1-C3 alkyl, 1-propenyl, 2-methyl2-propenyl, or 1-methylcyclopropyl, L 1 represents -NH-C(Ra) 2 -, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atoms, or methyl, ring A represents a substituted or unsubstituted group in which two hydrogen atoms are removed from imidazole, pyrazole, or thiazole, L 2 represents wherein
- the compound or a salt thereof of the present invention is still more preferably a compound represented by Formula (I) or a salt thereof, wherein X represents CH, R 1 represents chlorine or substituted C1-C3 alkyl, L 1 represents -NH-C(Ra) 2 -, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or methyl, ring A represents a substituted or unsubstituted group in which two hydrogen atoms are removed from imidazole, pyrazole, or thiazole, L 2 represents wherein
- the compound or a salt thereof of the present invention is most preferably a compound represented by Formula (I) or a salt thereof, wherein X represents CH, R 1 represents chlorine or tert-butyl, L 1 represents -NH-C(Ra) 2 -, wherein Ras are identical or different, and each represents a hydrogen atom, a deuterium atom, or methyl, ring A represents a substituted or unsubstituted group in which two hydrogen atoms are removed from imidazole, L 2 represents wherein
- Examples of specific compounds of the present invention include, but are not limited to, the compounds produced in the Examples below.
- Examples of preferable compounds of the present invention include the following:
- the compound represented by Formula (I) of the present invention can be produced, for example, through the following production methods or the methods described in the Examples. However, the production methods for the compound represented by Formula (I) of the present invention are not limited to these reaction examples.
- the reaction product obtained in each step can be subjected to the subsequent step after, or without, isolation and purification by known separation and purification methods, such as concentration, vacuum concentration, crystallization, solvent extraction, reprecipitation, and chromatography.
- a protecting group that can be easily converted to the functional group can be introduced if it is effective in each step, or so as to change the order of the steps.
- the protecting group used here may be the protecting groups etc. used in the method disclosed in the document " Protective Groups in Organic Synthesis," 5th edition, Greene and Wuts, John Wiley & Sons Inc., 2014 .
- the protecting group may be appropriately selected according to the reaction conditions of each step. After introducing a protecting group and performing reaction, the protecting group is optionally removed to thus yield a desired compound.
- step A compound (III) is used in an amount of 0.5 to 10 mol, and preferably 1 to 3 mol, per mol of compound (II).
- Step A is performed in a solvent inactive to the reaction by adding a condensation agent suitable as an amidation reagent, and stirring under cooling or heating, preferably at -20°C to 80°C, usually for 1 minute to 1 week.
- condensation agent used here examples include, but are not particularly limited to, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, benzotriazol-1-yloxy-tris-(dimethylamino)phosphonium hexafluorophosphate, benzotriazol-1-yloxy-tris-pyrrolidinophosphonium hexafluorophosphate, bromotris-(dimethylamino)phosphonium hexafluorophosphate, diphenylphosphoryl azide, 1,1'-carbonyldiimidazole, and the like.
- solvent used here examples include, but are not particularly limited to, toluene, methylene chloride, chloroform, THF, 1,4-dioxane, DMF, N,N-dimethylacetamide, NMP, 2-propanol, ethanol, methanol, water, and the like, and mixtures thereof. It is also possible to add additives, such as 1-hydroxybenzotriazole and a base, if necessary.
- the base include, but are not particularly limited to, inorganic bases, such as sodium carbonate, potassium carbonate, and sodium hydrogen carbonate; organic bases, such as triethylamine, N,N-diisopropylethylamine, and 4-dimethylaminopyridine; and mixtures thereof.
- step B known reaction methods for introducing a formyl group may be used. For example, the following methods are applicable:
- A, L 2 , PG 1 , R a , R 1 , R 2 , and X are as defined above.
- Step C is performed using compound (VI) in an amount of 0.5 to 10 mol, and preferably 0.5 to 2 mol, per mol of compound (V-1).
- Step C is performed in a solvent suitable for the reaction by using a reducing agent and optionally adding additives.
- the solvent include toluene, methylene chloride, chloroform, ethyl acetate, THF, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, DMSO, methanol, ethanol, 2-propanol, tert-butylalcohol, and the like, and mixed solvents thereof.
- Examples of the reducing agent used here include, but are not particularly limited to, a metal hydride complex, etc. (e.g., 0.1 mol or a large excessive molar amount of sodium borohydride, sodium cyanoborohydride, or triacetoxyborohydride.)
- Example of the additives used here include, but are not particularly limited to, acids, bases, and inorganic salts or organic salts. Examples include 0.01 mol or a large excessive molar amount of trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, potassium carbonate, sodium hydroxide, lithium hydroxide, sodium sulfate, magnesium sulfate, titanium isopropoxide, and the like.
- X 1 represents a leaving group
- A, L 2 , PG 1 , and R a are as defined above.
- Step D can be performed by using N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, bromine, iodine, etc.
- the solvent is not particularly limited as long as it does not affect the reaction.
- the reaction may be performed in an appropriate solvent that does not affect the invention, such as acetonitrile, ethyl acetate, THF, methanol, ethanol, DMF, N,N-dimethylacetamide, NMP, chloroform, and carbon tetrachloride.
- the reaction temperature is usually 0°C to 100°C, and preferably room temperature to reflux temperature.
- the reaction time is usually 10 minutes to 3 days, and preferably 30 minutes to 24 hours.
- the method for introducing a leaving group in step E is not particularly limited.
- sulfonyl esterification may be performed under the conditions such that methanesulfonyl chloride, toluenesulfonyl chloride, etc. and an appropriate base are used.
- halogenation may be performed under such conditions that a halogenating agent, such as carbon tetrachloride, carbon tetrabromide, or iodine, and triphenylphosphine etc. are used, or that a sulfonyl ester mentioned above is treated with lithium halide etc. and converted into a halogen group.
- A, L 2 , PG 1 , R a , R 1 , R 2 , X, and X 1 are as defined above.
- step F compound (VI) is used in an amount of 0.5 to 10 mol, and preferably 1 to 3 mol, per mol of compound (V-2).
- solvents include toluene, methylene chloride, chloroform, THF, 1,4-dioxane, DMF, N-methylpyrrolidone, DMSO, methanol, ethanol, isopropanol, tert-butyl alcohol, and the like, and mixed solvents thereof.
- Examples of the base used here include inorganic bases, such as sodium hydrogen carbonate, potassium carbonate, cesium carbonate, and potassium hydroxide; and organic bases, such as potassium-tert-butyrate, sodium-tert-butyrate, sodium methoxide, sodium ethoxide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, triethylamine, and N,N-diisopropylethylamine.
- inorganic bases such as sodium hydrogen carbonate, potassium carbonate, cesium carbonate, and potassium hydroxide
- organic bases such as potassium-tert-butyrate, sodium-tert-butyrate, sodium methoxide, sodium ethoxide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, triethylamine, and N,N-diisoprop
- compound (VII) is subjected to deprotection reaction of step G to obtain compound (X), and the obtained compound is subjected to amidation reaction of step H to thus produce a compound represented by Formula (I).
- PG 1 is hydrogen
- compound (VII) is subjected to amidation reaction of step H to produce a compound represented by Formula (I).
- the amine protecting group used here is not particularly limited. Examples include tert-butoxycarbonyl, benzyloxycarbonyl, and the like.
- step G the following methods can be used, although it varies depending on the type of the protecting group: solvolysis using an acid or a base according to the method disclosed in the document " Protective Groups in Organic Synthesis," fifth edition, Green and Wuts, John Wiley & Sons Inc., 2014 , or a similar method, i.e., a method comprising reacting with 0.01 mol or a large excessive molar amount of an acid, preferably trifluoroacetic acid, formic acid, or hydrochloric acid, or an equimolar to large excessive molar amount of a base, preferably sodium hydroxide, lithium hydroxide, etc.; chemical reduction using a metal hydride complex etc.; or catalytic reduction using a palladium-carbon catalyst, Raney nickel catalyst, etc.
- an acylating reagent is used in an amount of 0.5 to 10 mol, per mol of compound (X) obtained in the previous step, and the mixture is stirred in a solvent inactive to the reaction in the presence of a base under cooling to heating, preferably at -20°C to 80°C, usually for 3 days from the completion of the addition of the acylating reagent.
- solvent used here examples include, but are not particularly limited to, ethers, such as THF, diethyl ether, 1,4-dioxane, and 1,2-dimethoxyethane; halogenated hydrocarbons, such as dichloromethane, 1,2-dichloroethane, and chloroform; alcohols, such as methanol and ethanol; aromatic hydrocarbons, such as benzene, toluene, and xylene; DMF, DMSO, ethyl acetate, acetonitrile, water, and mixtures thereof.
- ethers such as THF, diethyl ether, 1,4-dioxane, and 1,2-dimethoxyethane
- halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, and chloroform
- alcohols such as methanol and ethanol
- aromatic hydrocarbons such as benzene, toluene, and xylene
- Examples of the base used here include inorganic bases, such as sodium carbonate, potassium carbonate, and sodium hydrogen carbonate; organic bases, such as triethylamine and N,N-diisopropylethylamine; and mixtures thereof.
- Examples of the acylating reagent include acid halide compounds and acid anhydrides. Examples of acid halide compounds include acryloyl chloride and the like.
- carboxylic acid is used in an amount of 0.5 to 10 mol, and preferably 1 to 3 mol, per mol of compound (X), and the mixture is stirred in a solvent inactive to the reaction in the presence of a condensation agent, and optionally in the presence of a base, under cooling to heating, preferably at -20°C to 80°C, usually for 1 minute to 3 days.
- condensation agent examples include, but are not particularly limited to, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, benzotriazol-1-yloxy-tris-(dimethylamino)phosphonium hexafluorophosphate, benzotriazol-1-yloxy-tris-pyrrolidinophosphonium hexafluorophosphate, bromotris-(dimethylamino)phosphonium hexafluorophosphate, diphenylphosphoric acid azide, 1,1'-carbonyldiimidazole, and the like.
- solvent used here examples include, but are not particularly limited to, toluene, methylene chloride, chloroform, THF, 1,4-dioxane, DMF, N,N-dimethylacetamide, NMP, 2-propanol, ethanol, methanol, water, and mixtures thereof.
- additives such as a base
- bases include, but are not particularly limited to, inorganic bases, such as sodium carbonate, potassium carbonate, and sodium hydrogen carbonate; organic bases, such as triethylamine, N,N-diisopropylethylamine, and 4-dimethylaminopyridine; and mixtures thereof.
- X 2 represents halogen
- PG 2 represents an ester protecting group
- A, R a , and X 1 are as defined above.
- a known reaction is used to produce a compound represented by Formula (XII-1) or Formula (XII-2) from a commercially available aromatic ring ester or from an aromatic ring ester that can be synthesized by known methods.
- A, L 2 , L 3 , PG 2 , R a , R 1 , R 2 , R 5 , X, and X 1 are as defined above.
- step I reaction of carboxylic acid ester hydrolysis well known in the field of organic chemistry is applicable.
- This hydrolysis reaction is not particularly limited, and may be performed, for example, by solvolysis using an acid or a base, i.e., a method comprising reacting with 0.01 mol or a large excessive molar amount of an acid, preferably trifluoroacetic acid, formic acid, hydrochloric acid, or the like, or an equimolar to large excessive molar amount of a base, preferably sodium hydroxide, lithium hydroxide, or the like.
- an acid or a base i.e., a method comprising reacting with 0.01 mol or a large excessive molar amount of an acid, preferably trifluoroacetic acid, formic acid, hydrochloric acid, or the like, or an equimolar to large excessive molar amount of a base, preferably sodium hydroxide, lithium hydroxide, or the like.
- X 3 represents a substituent that is convertible into cyano or the like. Examples include halogen, amine, ester, amide, carboxylic acid, and the like.
- X 4 represents a substituent that is convertible into hydrazine or the like. Examples include a protector etc. for halogen, amine, and hydrazine.
- R 1 , R 2 , and X are as defined above.
- step J a method well known in the field of organic chemistry is used to introduce a cyano group.
- a diazotization agent is used at -20°C to room temperature in an appropriate solvent to prepare a diazonium salt, and the obtained diazonium salt is added at -20 to 100°C to a solution of a base and a cyanating agent.
- usable reaction solvents include acidic solvents, such as hydrochloric acid, acetic acid, trifluoroacetic acid, and sulfuric acid; alcohols, such as methanol and ethanol; water; and mixtures thereof.
- Examples of the diazotization agent include sodium nitrite, isopentyl nitrite, and the like.
- Examples of the base include sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, and the like.
- Examples of the cyanating agent include sodium cyanide, potassium cyanide, copper cyanide, zinc cyanide, and the like, and mixtures thereof.
- the reaction may also be performed at room temperature to 200°C using a cyanating agent in an appropriate solvent. In the reaction, a palladium catalyst etc. may be added as additives.
- Examples of the cyanating agent include sodium cyanide, potassium cyanide, copper cyanide, zinc cyanide, and the like, and mixtures thereof.
- the usable reaction solvent is not limited as long as it does not affect the reaction.
- examples include ethers, such as THF and 1,4-dioxane; alcohols, such as methanol and ethanol; amides, such as DMF, N,N-dimethylacetamide, and N-methyl-2-pyrrolidone; hydrocarbons, such as toluene; acetonitrile; dimethylsulfoxide; water; and mixed solvents thereof.
- step K for example, when X 4 in Formula (XVII) is halogen, hydrazine etc. may be reacted at 20 to 200°C in an appropriate solvent. It is also possible to subject hydrazine etc. protected by a protecting group to cross-coupling reaction using a palladium catalyst, and thereafter remove the hydrazine protecting group.
- the reaction solvent usable here is not limited as long as it does not affect the reaction.
- Examples include ethers, such as THF and 1,4-dioxane; alcohols, such as methanol and ethanol; amides, such as DMF, N,N-dimethylacetamide, and N-methyl-2-pyrrolidone; hydrocarbons, such as toluene; acetonitrile; dimethylsulfoxide; water; and mixed solvents thereof.
- ethers such as THF and 1,4-dioxane
- alcohols such as methanol and ethanol
- amides such as DMF, N,N-dimethylacetamide, and N-methyl-2-pyrrolidone
- hydrocarbons such as toluene
- acetonitrile such as toluene
- dimethylsulfoxide water
- mixed solvents thereof such as toluene
- Examples of the palladium catalyst usable here include palladium acetate, palladium chloride, tetrakis(triphenylphosphine)palladium, dichlorobis(triphenylphosphine)palladium, dichloro(1,1'-bis(diphenylphosphino)ferrocene)palladium, dichlorobisacetonitrile palladium, and tris(dibenzylideneacetone) dipalladium (0). It is appropriate to use the palladium catalyst in an amount of 0.001 to 1 mol, per mol of the compound represented by formula (XVII).
- Examples include organic bases, such as potassium-tert-butyrate, sodium-tert-butyrate, sodium methoxide, sodium ethoxide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, and potassium hexamethyldisilazide; and inorganic bases, such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, sodium phosphate, and potassium phosphate. Although it varies depending on the reaction temperature, the reaction may be performed for 30 minutes to 24 hours.
- the hydrazine protecting group may be removed, for example, by the method disclosed in the document " Protective Groups in Organic Synthesis,” fifth edition, Greene and Wuts, John Wiley & Sons Inc., 2014 , or a similar method, although it varies depending on the type of the protecting group used.
- any of the isomers and mixtures thereof are included within the scope of the compound of the present invention unless otherwise specified.
- the compound of the present invention has optical isomers, racemic mixtures and the optical isomers separated from a racemic mixture are also included within the scope of the compound of the present invention unless otherwise specified.
- the compound or a salt thereof of the present invention may be in the form of amorphous or crystals. Single crystals and polymorphic mixtures are included within the scope of the compound or a salt thereof of the present invention. Such crystals can be produced by crystallization according to a crystallization method known in the art.
- the compound or a salt thereof of the present invention may be a solvate (e.g., a hydrate) or a non-solvate. Any of such forms are included within the scope of the compound or a salt thereof of the present invention.
- Compounds labeled with an isotope e.g., 2 H, 3 H, 13 C, 14 C, 35 S, 125 I
- an isotope are also included within the scope of the compound or a salt thereof of the present invention.
- the salts of the compound of the present invention refer to any pharmaceutically acceptable salts; examples include base addition salts and acid addition salts.
- the compound or a salt thereof of the present invention also encompass prodrugs thereof.
- a prodrug refers to a compound that can be converted to the compound or a salt thereof of the present invention through a reaction with an enzyme, gastric acid, or the like under physiological conditions in vivo, i.e., a compound that can be converted to the compound or a salt thereof of the present invention by enzymatic oxidation, reduction, hydrolysis, or the like; or a compound that can be converted to the compound or a salt thereof of the present invention by hydrolysis or the like with gastric acid or the like.
- the prodrug may be compounds that can be converted to the compound or a salt thereof of the present invention under physiological conditions, such as those described in Iyakuhin no Kaihatsu, "Development of Pharmaceuticals," Vol. 7, Molecular Design, published in 1990 by Hirokawa Shoten Co., pp. 163-198 .
- a pharmaceutical carrier can be added, if required, thereby forming a suitable dosage form according to prevention and treatment purposes.
- the dosage form include oral preparations, injections, suppositories, ointments, inhalations, patches, and the like.
- Such dosage forms can be formed by methods conventionally known to a person skilled in the art.
- various conventional organic or inorganic carrier materials used as preparation materials may be blended as an excipient, binder, disintegrant, lubricant, or colorant in solid preparations; or as a solvent, solubilizing agent, suspending agent, isotonizing agent, buffer, or soothing agent in liquid preparations.
- pharmaceutical preparation additives such as antiseptics, antioxidants, colorants, sweeteners, and stabilizers, may also be used, if required.
- Oral solid preparations are prepared as follows. After an excipient is added optionally with a binder, disintegrant, lubricant, colorant, taste-masking or flavoring agent, etc. to the compound or a salt thereof of the present invention, the resulting mixture is formulated into tablets, coated tablets, granules, powders, capsules, or the like by ordinary methods.
- a pH regulator, a buffer, a stabilizer, an isotonizing agent, a local anesthetic, and the like may be added to the compound of the present invention; and the mixture may be formulated into a subcutaneous, intramuscular, or intravenous injection according to an ordinary method.
- the amount of the compound of the present invention to be incorporated in each of such dosage unit forms depends on the condition of the patient to whom the compound is administered, the dosage form, etc. In general, for an oral agent, the amount of the compound is preferably about 0.05 to 1000 mg per dosage unit form. For an injection, the amount of the compound is preferably about 0.01 to 500 mg per dosage unit form, and for a suppository, the amount of the compound is preferably about 1 to 1000 mg per dosage unit form.
- the daily dose of the medicine in such a dosage form varies depending on the condition, body weight, age, sex, etc. of the patient, and cannot be unconditionally determined.
- the daily dose for an adult (body weight: 50 kg) of the compound of the present invention may be generally about 0.05 to 5000 mg, and preferably 0.1 to 1000 mg.
- the compound or a salt thereof of the present invention has excellent KRAS inhibitory activity against KRAS G12C mutation-positive cancer cells, and also has excellent selectivity for wild-type KRAS normal cells. Therefore, the compound or a salt thereof of the present invention is useful as an antitumor agent against KRAS G12C mutation-positive cancer cells, and has the advantage of fewer side effects.
- the compound or a salt thereof of the present invention inhibits the KRAS function and is useful as a pharmaceutical preparation for preventing and/or treating KRAS-associated signaling-related diseases.
- an administration of the compound or a salt thereof of the present invention, in combinaion with an effective amount of one or more other antitumor agents can prevent and/or treat KRAS-associated signaling-related diseases (in particular, tumors).
- KRAS is involved in various signaling transduction as RAS-associated signaling; KRAS mainly activates, but is not limited to, RAF, PI3K, RAL-GEF, and the like.
- the diseases include diseases whose incidence can be reduced, and whose symptoms can be remitted, relieved, and/or completely cured by deleting, suppressing, and/or inhibiting their functions. Examples of such diseases include, but are not limited to, cancers, autoimmune diseases, macroglobulinemia, and the like.
- tumors targeted in the present invention include, but are not particularly limited to, head and neck cancer, digestive organ cancer (esophageal cancer, stomach cancer, duodenal cancer, liver cancer, biliary cancer (e.g., gallbladder and bile duct cancer), pancreatic cancer, colorectal cancer (e.g., colon cancer, and rectal cancer), etc.), lung cancer (e.g., non-small-cell lung cancer, small-cell lung cancer, and mesothelioma), breast cancer, genital cancer (ovarian cancer, uterine cancer (e.g., cervical cancer and endometrial cancer), etc.), urological cancer (e.g., kidney cancer, bladder cancer, prostate cancer, and testicular tumor), hematopoietic tumor (e.g., leukemia, malignant lymphoma, and multiple myeloma), osteosarcoma, soft-tissue sarcoma, skin cancer, brain tumor, and the like.
- lung cancer e.g.
- the reagents used in the Examples are commercially available products unless indicated otherwise. Prepacked columns manufactured by Shoko Scientific Co., Ltd., or Biotage were used in silica gel column chromatography and basic silica gel column chromatography. An AL400 spectrometer (400 MHz; JEOL Ltd. (JEOL)) or Mercury 400 (400 MHz; Varian) spectrometer was used for NMR spectra. For a deuterated solvent containing tetramethylsilane, tetramethylsilane was used as the internal reference. In other cases, measurement was performed using an NMR solvent as the internal reference. All ⁇ values are indicated in ppm. Microwave reaction was performed using an Initiator (trademark) manufactured by Biotage.
- Rhodium carbon (Rh 5%) (100 mg) was added to a solution of 6-chloro-5-vinyl-1H-indazole-3-amine (135 mg) obtained in Production Example 2 in THF (1.0 mL) and ethanol (1.0 mL) in a nitrogen atmosphere, and the reaction system was subjected to hydrogen replacement, followed by stirring for 5 days. The reaction system was then subjected to nitrogen replacement, and the reaction mixture was filtered. The solvent was concentrated under reduced pressure, and the obtained residue was purified by column chromatography (ethyl acetate:ethanol), thereby obtaining the title compound (31 mg).
- step 2 The procedure of Production Example 20 (step 2) was performed except that tert-butyl amine was used instead of cyclopropylamine used in Production Example 20 (step 2), thereby obtaining the title compound.
- step 1 The procedure of Production Example 13 (step 1) was performed except that (S)-1-(tert-butoxycarbonyl)-3-pyrrolidinol was used instead of methanol used in Production Example 13 (step 1), thereby obtaining the title compound (10.61 g, >99%ee).
- step 1 The procedure of Production Example 13 (step 1) was performed except that (R)-1-(tert-butoxycarbonyl)-3-pyrrolidinol was used instead of methanol used in Production Example 13 (step 1), thereby obtaining the title compound (659 mg, >99%ee).
- Production Example 42 (step 1), N-bromosuccinimide was used instead of N-chlorosuccinimide. Thereafter, Production Example 42 (steps 2 and 3) was performed, and the synthesized ethyl 3-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-bromo-1-methyl-1H-pyrazole-5-carboxylate (0.23 g) was dissolved in 1,4-dioxane (1.0 mL).
- Methyl boric acid (0.046 g), a potassium phosphate aqueous solution (2N, 0.10 mL), and a (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride dichloromethane adduct (0.004 g) were added thereto.
- Trifluoroacetic acid (1.00 mL) was added to a solution of methyl (R)-1-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-4-chloro-2-formyl-1H-imidazole-5-carboxylate (2.16 g) obtained in Production Example 25 and 5-(tert-butyl)-6-chloro-1H-indazole-3-amine (1.34 g) obtained in Production Example 1 in THF (30 mL), followed by stirring at room temperature for 30 minutes. Sodium triacetoxyborohydride (600 mg) was added every 60 minutes 5 times. Thereafter, the mixture was stirred at room temperature for 80 minutes.
- Trifluoroacetic acid (10 ⁇ L) was added to a solution of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine (18.3 mg) obtained in Production Example 1 and N-(1-acryloylazetidin-3-yl)-2-formyl-1-methyl-1H-imidazole-5-carboxamide (26.0 mg) obtained in Production Example 35 in dichloromethane (2.00 mL), followed by adding sodium triacetoxyborohydride (30 mg). After stirring at room temperature for 1 hour, a saturated sodium hydrogen carbonate aqueous solution and ethyl acetate were added to the reaction mixture. The organic layer was separated and washed with saturated saline, followed by drying over sodium sulfate. The solvent was evaporated under reduced pressure, and the obtained residue was purified by column chromatography (chloroform:ethanol), thereby obtaining the title compound (25.2 mg) .
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that tert-butyl 3-(2-formyl-1,4-dimethyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate obtained in Production Example 36 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (45.8 mg) .
- Example 4 The procedure of Example 4 (steps 1 and 2) was performed except that ethyl 3-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-chloro-1-methyl-1H-pyrazole-5-carboxylate (12.6 mg) obtained in Production Example 42 was used instead of methyl 2-(1-((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)ethyl)-1-methyl-1H-imidazole-5-carboxylate used in Example 4 (step 1), thereby obtaining the title compound (7.7 mg) .
- Example 2 The procedure of Example 2 (steps 1 to 5) was performed except that 2-bromothiazole-5-carboxylic acid was used instead of 2-bromo-4-methylthiazole-5-carboxylic acid used in Example 2 (step 1), thereby obtaining the title compound (4.90 mg).
- Example 4 The procedure of Example 4 (step 2) was performed except that 3-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-1,4-dimethyl-1H-pyrazole-5-carboxylic acid obtained in Production Example 43 was used instead of 2-[1-[(5-tert-butyl-6-chloro-1H-indazol-3-yl)amino]ethyl]-3-methylimidazole-4-carboxylic acid used in Example 4 (step 2), thereby obtaining the title compound (1.29 mg).
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that tert-butyl 3-(2-formyl-1-isopropyl-4-methyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (91.0 mg) obtained in Production Example 37 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (31.0 mg).
- Example 21 The procedure of Example 21 (steps 4 to 6) was performed except that 2-(hydroxymethyl)-4-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazole-5-carboxylic acid (162 mg) obtained in Production Example 22 was used instead of 1-(difluoromethyl)-2-(hydroxymethyl)-4-methyl-1H-imidazole-5-carboxylic acid used in Example 21 (step 4), thereby obtaining the title compound (25.7 mg) .
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that tert-butyl 3-(4-ethyl-2-formyl-1-methyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (55.4 mg) obtained in Production Example 40 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (30.5 mg).
- Example 2 The procedure of Example 2 (step 5) was performed except that tert-butyl 3-(2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-(difluoromethyl)-1-isopropyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (1.48 g) obtained in Production Example 50 was used instead of tert-butyl 3-(2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-methylthiazole-5-carboxamide)aminoazetidine-1-carboxylate used in Example 2 (step 5), thereby obtaining the title compound (503 mg) .
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that tert-butyl 3-(4-chloro-2-formyl-1-isopropyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (111 mg) obtained in Production Example 38 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (64 mg).
- Example 1 The procedure of Example 1 was performed except that 6-chloro-5-methyl-1H-indazole-3-amine obtained in Production Example 5 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 1, thereby obtaining the title compound (15.9 mg).
- Example 1 The procedure of Example 1 was performed except that 6-chloro-5-vinyl-1H-indazole-3-amine obtained in Production Example 2 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 1, thereby obtaining the title compound (14.8 mg) .
- Example 1 The procedure of Example 1 was performed except that 6-chloro-5-ethyl-1H-indazole-3-amine obtained in Production Example 3 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 1, thereby obtaining the title compound (35.2 mg) .
- Example 1 The procedure of Example 1 was performed except that 5-(tert-butyl)-6-chloro-1H-pyrazolo[4,3-b]pyridine-3-amine obtained in Production Example 4 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 1, thereby obtaining the title compound (21.4 mg).
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that 5-(tert-butyl)-6-methyl-1H-indazole-3-amine obtained in Production Example 6 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 2 (step 4), and that tert-butyl 3-(2-formyl-1,4-dimethyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate obtained in Production Example 36 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (18.6 mg) .
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that 5-(tert-butyl)-1H-indazole-3-amine obtained in Production Example 7 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 2 (step 4), and that tert-butyl 3-(2-formyl-1-isopropyl-4-methyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate obtained in Production Example 37 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (29.1 mg) .
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that 6-chloro-5-(3,3,3-trifluoroprop-1-en-2-yl)-1H-indazole-3-amine obtained in Production Example 8 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 2 (step 4), and that tert-butyl 3-(4-chloro-2-formyl-1-isopropyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate obtained in Production Example 38 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (8.0 mg).
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that 6-chloro-5-(1-(trifluoromethyl)cyclopropyl)-1H-indazole-3-amine obtained in Production Example 9 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 2 (step 4), and that tert-butyl 3-(4-chloro-2-formyl-1-isopropyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate obtained in Production Example 38 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (10.0 mg) .
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that 6-chloro-5-isopropyl-1H-indazole-3-amine obtained in Production Example 10 was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 2 (step 4), and that tert-butyl 3-(4-chloro-2-formyl-1-isopropyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate obtained in Production Example 38 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (23.3 mg) .
- Example 46 The procedure of Example 46 (step 1) was performed except that 1-(4-aminopiperidin-1-yl)prop-2-en-1-one hydrochloride (9.7 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (21.4 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl 3-(methylamino)azetidine-1-carboxylate (9.5 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (15.0 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl piperazine-1-carboxylate (17.3 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (16.4 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl N-(azetidin-3-yl)-N-methyl carbamate hydrochloride (23.7 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (19.9 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that cis-tert-butyl 3-amino-2-methylazetidine-1-carboxylate (17.3 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (18.0 mg).
- Example 46 The procedure of Example 46 (step 1) was performed except that 1-(4-amino-3,3-difluoropyrrolidin-1-yl)prop-2-en-1-one trifluoroacetate (26.9 mg) obtained in Production Example 28 was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (7.7 mg).
- Example 46 The procedure of Example 46 (step 1) was performed except that (R)-1-(7-amino-5-azaspiro[2.4]heptan-5-yl)prop-2-en-1-one trifluoroacetate (38.9 mg) obtained in Production Example 29 was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (22.3 mg).
- Example 46 The procedure of Example 46 (step 1) was performed except that 1-((3R,4R)-3-amino-4-methylpyrrolidin-1-yl)prop-2-en-1-one trifluoroacetate (37.3 mg) obtained in Production Example 30 was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (22.2 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3S,4R)-3-amino-4-hydroxy-pyrrolidine-1-carboxylate (18.7 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (21.8 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3S,4R)-3-amino-4-fluoropyrrolidine-1-carboxylate (18.9 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (24.2 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3R,4R)-3-amino-4-(hydroxymethyl)pyrrolidine-1-carboxylate (20.0 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (20.2 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that trans-tert-butyl 3-amino-2-methylazetidine-1-carboxylate (22.6 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (16.2 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3R,4S)-3-amino-4-methylpyrrolidine-1-carboxylate (28.2 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (16.3 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3S,4R)-3-amino-4-methoxypyrrolidine-1-carboxylate (26.9 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (20.7 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3S,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate (18.7 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (18.5 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3S,4S)-3-amino-4-methoxypyrrolidine-1-carboxylate (20.0 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), and that acrylic anhydride was used instead of acryloyl chloride used in Example 46 (step 2), thereby obtaining the title compound (19.3 mg) .
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3S,4S)-3-amino-4-fluoropyrrolidine-1-carboxylate (21.1 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (6.1 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3R,4R)-3-amino-4-(cyanomethyl)pyrrolidine-1-carboxylate (20.9 mg) obtained in Production Example 31 was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (12.9 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3R,4R)-3-amino-4-(fluoromethyl)pyrrolidine-1-carboxylate (17.9 mg) obtained in Production Example 32 was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (11.3 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3R,4R)-3-amino-4-(methoxymethyl)pyrrolidine-1-carboxylate (16.0 mg) obtained in Production Example 33 was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (18.5 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3R,4R)-3-amino-4-((dimethylamino)methyl)pyrrolidine-1-carboxylate (10.2 mg) obtained in Production Example 34 was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (7.9 mg).
- Example 46 The procedure of Example 46 (steps 1 and 2) was performed except that tert-butyl (3R,4R)-3-amino-4-ethylpyrrolidine-1-carboxylate (8.6 mg) was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (5.2 mg).
- Example 46 The procedure of Example 46 (step 1) was performed except that 2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-(difluoromethyl)-1-methyl-1H-imidazole-5-carboxylic acid (20 mg) obtained in Production Example 45 was used instead of 2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-1,4-dimethyl-1H-imidazole-5-carboxylic acid used in Example 46 (step 1), and that 1-((3R,4R)-3-amino-4-methylpyrrolidin-1-yl)prop-2-en-1-one trifluoroacetate (39.1 mg) obtained in Production Example 30 was used instead of 3-N-BOC-aminoazetidine used in Example 46 (step 1), thereby obtaining the title compound (20.4 mg).
- Example 28 The procedure of Example 28 (steps 1 to 3) was performed except that 4-chloro-1-methyl-1H-imidazole-5-carboxylic acid (78.6 mg) obtained in Production Example 13 was used instead of 4-cyano-1-methyl-1H-imidazole-5-carboxylic acid used in Example 28 (step 1), and that (R)-(+)-1-BOC-3-aminopyrrolidine (119 mg) was used instead of 1-Boc-3-aminoazetidine used in Example 28 (step 1), thereby obtaining the title compound (18.0 mg) .
- Example 70 The procedure of Example 70 (step 1) was performed except that 2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-fluoro-1-methyl-1H-imidazole-5-carboxylic acid obtained in Example 72 (step 1) was used instead of 2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-(difluoromethyl)-1-methyl-1H-imidazole-5-carboxylic acid used in Example 70 (step 1), and that 1-((3R,4R)-3-amino-4-methylpyrrolidin-1-yl)prop-2-en-1-one trifluoroacetate (37.2 mg) obtained in Production Example 30 was used instead of tert-butyl (3S,4S)-3-amino-4-fluoropyrrolidine-1-carboxylate used in Example 70 (step 1), thereby obtaining
- Example 70 The procedure of Example 70 (steps 1 and 2) was performed except that 2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-fluoro-1-methyl-1H-imidazole-5-carboxylic acid obtained in Example 72 (step 1) was used instead of 2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-(difluoromethyl)-1-methyl-1H-imidazole-5-carboxylic acid used in Example 70 (step 1), thereby obtaining the title compound (12 mg).
- Example 28 The procedure of Example 28 (steps 1 to 3) was performed except that 4-chloro-1-methyl-1H-imidazole-5-carboxylic acid (90.0 mg) obtained in Production Example 13 was used instead of 4-cyano-1-methyl-1H-imidazole-5-carboxylic acid used in Example 28 (step 1), and that tert-butyl (3S,4S)-3-amino-4-fluoropyrrolidine-1-carboxylate (126 mg) was used instead of 1-Boc-3-aminoazetidine used in Example 28 (step 1), thereby obtaining the title compound (13.7 mg).
- Example 28 The procedure of Example 28 (steps 1 to 3) was performed except that 1-methyl-1H-5-imidazole carboxylic acid (252 mg) was used instead of 4-cyano-1-methyl-1H-imidazole-5-carboxylic acid used in Example 28 (step 1), and that tert-butyl (3R)-3-(methylamino)pyrrolidine-1-carboxylate (450 mg) was used instead of 1-Boc-3-aminoazetidine used in Example 28 (step 1), thereby obtaining the title compound (49.1 mg).
- Example 70 The procedure of Example 70 (step 1) was performed except that 2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-chloro-1-methyl-1H-imidazole-5-carboxylic acid (35 mg) obtained in Production Example 47 was used instead of 2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-(difluoromethyl)-1-methyl-1H-imidazole-5-carboxylic acid used in Example 70 (step 1), and that 1-((3R,4R)-3-amino-4-methylpyrrolidin-1-yl)prop-2-en-1-one trifluoroacetate (37.2 mg) obtained in Production Example 30 was used instead of tert-butyl (3S,4S)-3-amino-4-fluoropyrrolidine-1-carboxylate used in Example 70 (step 1), thereby
- Trifluoroacetic acid (1.5 mL) was added to tert-butyl 3-(2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-1,4-dimethyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (12.9 mg) obtained in Production Example 49, followed by stirring at room temperature for 15 minutes. The reaction mixture was concentrated, and toluene was added to the obtained residue, followed by concentrating the residue twice.
- Trifluoroacetic acid (1.5 mL) was added to tert-butyl 3-(2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-1-isopropyl-4-methyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (165 mg) obtained in Production Example 48, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated, and toluene was added to the obtained residue, followed by concentrating the residue twice.
- Trifluoroacetic acid (1.5 mL) was added to tert-butyl 3-(2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-1-isopropyl-4-methyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (47.6 mg) obtained in Production Example 48, followed by stirring at room temperature for 15 minutes. The reaction mixture was concentrated, and toluene was added to the obtained residue, followed by concentrating the residue twice.
- Example 82 The procedure of Example 82 was performed except that CIS-3-chloroacrylic acid (14.8 mg) was used instead of 2-butynoic acid used in Example 82, thereby obtaining the title compound (10.0 mg).
- Example 80 The procedure of Example 80 was performed except that tert-butyl 3-(2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-(difluoromethyl)-1-isopropyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (29.9 mg) obtained in Production Example 50 was used instead of tert-butyl 3-(2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-1,4-dimethyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate used in Example 80, thereby obtaining the title compound (16.4 mg).
- Example 82 The procedure of Example 82 was performed except that (E)-4-methoxybut-2-enoic acid (17.6 mg) was used instead of 2-butynoic acid used in Example 82, thereby obtaining the title compound (1.4 mg).
- Example 81 The procedure of Example 81 was performed except that ethene sulfonyl chloride (3.64 ⁇ L) was used instead of crotonoyl chloride used in Example 81, thereby obtaining the title compound (3.2 mg).
- Example 88 steps 1 to 3
- Example 87 steps 4 to 6
- 2-methoxyethanol 227 mg
- 3,5-dimethoxybenzyl alcohol used in Example 88 (step 1)
- Example 91 The procedure of Example 91 (step 9) was performed except that acetaldehyde (20 mg) was used instead of the formaldehyde solution used in Example 91 (step 9), thereby obtaining the title compound (3.12 mg).
- Example 91 The procedure of Example 91 (step 9) was performed except that acetone (20 mg) was used instead of the formaldehyde solution used in Example 91 (step 9). After purification by preparative reversed-phase HPLC (water:acetonitrile (0.1% formic acid)), the solvent was concentrated, thereby obtaining the title compound (8.33 mg).
- Example 91 The procedure of Example 91 (steps 1 to 9) was performed except that N-(tert-butoxycarbonyl)-DL-prolinol was used instead of 1-(tert-butoxycarbonyl)-3-pyrrolidinol used in Example 91 (step 1), and that acetone (20 mg) was used instead of the formaldehyde solution used in Example 91 (step 9), thereby obtaining the title compound (3.5 mg).
- Example 98 The procedure of Example 98 (steps 1 to 5) was performed except that 2,2-difluoroethanol was used instead of 3-cyclopenten-1-ol used in Example 98 (step 1), thereby obtaining the title compound (72 mg).
- Example 98 The procedure of Example 98 (steps 1 to 5) was performed except that tetrahydro-4H-pyran-4-ol was used instead of 3-cyclopenten-1-ol used in Example 98 (step 1), thereby obtaining the title compound (25.3 mg).
- Example 98 The procedure of Example 98 (steps 1 to 5) was performed except that (S)-(+)-3-hydroxytetrahydrofuran was used instead of 3-cyclopenten-1-ol used in Example 98 (step 1), thereby obtaining the title compound (54.1 mg).
- Example 98 The procedure of Example 98 (steps 1 to 5) was performed except that tetrahydro-2H-pyran-3-ol was used instead of 3-cyclopenten-1-ol used in Example 98 (step 1), thereby obtaining the title compound (18.5 mg).
- Example 98 The procedure of Example 98 (steps 1 to 5) was performed except that cyclopentanol was used instead of 3-cyclopenten-1-ol used in Example 98 (step 1), thereby obtaining the title compound (100 mg).
- Trifluoroacetic acid (1.0 mL) was added to tert-butyl 3-(5-((1-acryloylazetidin-3-yl)carbamoyl)-2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-chloro-1H-imidazol-1-yl)azetidine-1-carboxylate (30 mg) obtained in Example 106 (step 2). The mixture was stirred and concentrated, followed by adding THF (1.0 mL), N,N-diisopropylethylamine (56 ⁇ L), and acetic anhydride (5 ⁇ L) to the obtained residue.
- THF 1.0 mL
- N,N-diisopropylethylamine 56 ⁇ L
- acetic anhydride (5 ⁇ L)
- Example 98 The procedure of Example 98 (steps 1 to 5) was performed except that cyclohexanol was used instead of 3-cyclopenten-1-ol used in Example 98 (step 1), thereby obtaining the title compound (20.5 mg).
- Example 97 The procedure of Example 97 (steps 1 to 4) was performed except that cyclopentylmethanol was used instead of (R)-(-)-3-hydroxytetrahydrofuran used in Example 97 (step 1), thereby obtaining the title compound (140 mg).
- Example 98 The procedure of Example 98 (steps 1 to 5) was performed except that (-)-menthol was used instead of 3-cyclopenten-1-ol used in Example 98 (step 1), thereby obtaining the title compound (10.7 mg).
- Example 97 The procedure of Example 97 (steps 1 to 4) was performed except that 4-methoxycyclohexanol was used instead of (R)-(-)-3-hydroxytetrahydrofuran used in Example 97 (step 1), thereby obtaining the title compound (140 mg).
- Example 91 step 9
- 2-(((1-acetyl-5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-N-(1-acryloylazetidin-3-yl)-4-chloro-1-(piperidin-3-yl)-1H-imidazole-5-carboxamide trifluoroacetate (20 mg) obtained in Example 117 (step 2) was used instead of N-(1-acryloylazetidin-3-yl)-2-(((5-(tert-butyl)-6-chloro-1H-indazol-3-yl)amino)methyl)-4-(difluoromethyl)-1-(pyrrolidin-3-yl)-1H-imidazole-5-carboxamide formate used in Example 91 (step 9), thereby obtaining the title compound (8.05 mg).
- Example 113 The procedure of Example 113 (steps 1 and 2) was performed except that oxetane-3-one (11.5 mg) was used instead of difluoroacetaldehyde ethyl hemiacetal used in Example 113 (step 1), thereby obtaining the title compound (29.4 mg).
- Example 122 The procedure of Example 122 (steps 1 and 2) was performed except that allyl bromide was used instead of benzyl bromide used in Example 122 (step 1), thereby obtaining the title compound (135 mg).
- Example 125 The procedure of Example 125 (steps 1 to 3) was performed except that tert-butyl (2R,4S)-4-hydroxy-2-methyl-pyrrolidine-1-carboxylate (501 mg) was used instead of tert-butyl (2S,3S)-3-hydroxy-2-methyl-pyrrolidine-1-carboxylate used in Example 125 (step 1), thereby obtaining the title compound (71.8 mg).
- Example 1 The procedure of Example 1 was performed except that 5-bromo-6-chloro-1H-indazole-3-amine obtained in Production Example 5 (step 1) was used instead of 5-(tert-butyl)-6-chloro-1H-indazole-3-amine used in Example 1, thereby obtaining the title compound (4.9 mg).
- Example 2 The procedure of Example 2 (steps 4 and 5) was performed except that tert-butyl 3-(2-formyl-1-methyl-4-phenyl-1H-imidazole-5-carboxamide)azetidine-1-carboxylate (84 mg) obtained in Production Example 39 was used instead of tert-butyl 3-(2-formyl-4-methylthiazole-5-carboxamide)azetidine-1-carboxylate used in Example 2 (step 4), thereby obtaining the title compound (66.0 mg).
- the following is a list of the compounds of Examples 1 to 126 and Reference Examples 1 to 3.
- Test Example 1 A test of compounds on whether to bind to KRASG12C
- Test compounds were prepared in the form of a 10 mM DMSO solution.
- K-Ras4B (1-169) and G12C K-Ras4B (1-169) proteins were mixed and diluted with a buffer (1 ⁇ TBS, 0.1mM TCEP) to prepare individual 1 ⁇ M protein solutions.
- a 10 mM test compound was diluted tenfold with DMSO to make a 1 mM solution, and then diluted fivefold with DMSO to make a 200 ⁇ M solution. The 200 ⁇ M solution was further diluted fivefold to make a 40 ⁇ M solution.
- the final compound concentration was 10 ⁇ M, 1 ⁇ L of a 200 ⁇ M test compound was added to 19 ⁇ L of a 1 ⁇ M protein solution.
- a spectrum of a polyvalent ion was collectively converted to a molecular weight by using OpenLynx software by the MaxEnt technique, and a compound binding rate was obtained from the ratio of a signal intensity that corresponds to the molecular weight of a protein to a signal intensity that corresponds to the molecular weight of a compound binding to the protein.
- test compounds were measured at their final compound concentration of 2 ⁇ M.
- a binding rate of 80% or more is rated “A”
- a binding rate of 60% or more and less than 80% is rated “B”
- a binding rate of 40% or more and less than 60% is rated “C”
- a binding rate of 20% or more and less than 40% is rated “D”
- a binding rate of less than 20% is rated “E.”
- the following table shows the results. Almost no compounds of the present invention binded to K-Ras4B (1-169).
- the "binding rate” (%) for each of K-Ras4B (1-169) and G12C K-Ras4B (1-169) refers to the ratio of the signal intensity of binded forms to the sum of the singal intensity of non-binded forms and the singal intensity of binded forms.
- Test Example 2 Evaluation of inhibitory activity of compounds on KRAS G12C nucleotide (GDP-GTP) exchange reaction
- KRAS G12C For the preparation of KRAS G12C to which Bodipy FL GDP was bound, first, 50 ⁇ M KRAS G12C (amino acid region: 1-169) and 1 mM Bodipy FL GDP (Invitrogen, G22360) were incubated for 1 hour in a buffer (20 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM DTT) in ice in the presence of 2.5 mM EDTA. Thereafter, MgCl 2 with a final concentration of 10 mM was added, and the mixture was incubated at room temperature for 30 minutes. The protein was allowed to pass through a NAP-5 column to remove free nucleotides and was used for compound evaluation.
- a buffer (20 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM DTT) in ice in the presence of 2.5 mM EDTA.
- MgCl 2 with a final concentration of 10 mM
- the compound of the present invention was diluted stepwise with dimethyl sulfoxide (DMSO). Subsequently, a solution of the gradually diluted compound of the present invention in DMSO (the final concentration of DMSO: 5%) and KRAS G12C (25 nM) bound to Bodipy FL GDP were added to a reaction buffer (20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl 2 , 2 mM DTT, 0.1% Tween20), followed by preincubation at 25°C for 4 hours.
- DMSO dimethyl sulfoxide
- Example IC50 (nM) Example IC50 (nM)
- Example IC50 (nM) Example IC50 (nM) 1 16 34 13 67 24 100 14 2 365 35 8 68 99 101 7 3 9 36 19 69 6650 102 5 4 1560 37 5479 70 79 103 5 5 10 38 2168 71 117 104 9 6 791 39 870 72 71 105 8 7 4257 40 27 73 52 106 8 783 41 14 74 36 107 4 9 3143 42 68 75 16 108 9 10 129 43 809 76 13 109 23 11 1064 44 180 77 142 110 9 12 16 45 24 78 20 111 15 13 15 46 92 79 122 112 5 14 24 47 1729 80 63 113 5 15 84 48 126 81 2634 114 7 16 25 49 208 82 209 115 7 17 17 50 4276 83 2347 116
- Test Example 3 A measurement test of growth inhibition activity on KRAS-G12C mutant cell line (NCI-H358) (in vitro)
- NCI-H358 cells (ATCC, Cat#: CRL-5807), which are a KRAS-G12C mutant human lung cancer cell line, were suspended in a 10% fetal bovine serum-containing RPMI1640 medium (manufactured by Fujifilm Wako Pure Chemical Corporation.). The cell suspension was seeded into each well of a 384-well flat-bottom microplate and cultured in an incubator containing 5% CO 2 gas at 37°C for 1 day. The test compound was dissolved in DMSO, and diluted with DMSO to give a concentration 500 times the final concentration.
- the solution of the test compound in DMSO was diluted with the medium used for suspending cells and added to each well of the cell-culture plate to give a DMSO final concentration of 0.2%, followed by culture in an incubator containing 5% CO 2 gas at 37°C for another 3 days.
- the cell count after 3-day culture in the presence of the compound was measured using CellTiter-Glo2.0 (manufactured by Promega Corporation) in accordance with the protocol recommended by Promega Corporation.
- the growth inhibition rate was calculated from the following equation, and the concentration of the test compound at which 50% inhibition was achieved (IC50 (nM)) was determined.
- IC50 (nM) concentration of the test compound at which 50% inhibition was achieved
- Example IC50 (nM) Example IC50 (nM)
- Example IC50 (nM) Example IC50 (nM)
- Example IC50 (nM) 3 114 76 232 104 91 115 56 13 135 78 350 105 76 123 21 29 34 93 40 106 42 124 19 33 153 97 52 107 78 126 35 35 67 101 54 112 52
- Reference Example 1 >10000 64 241 102 69 113 22 75 142 103 29 114 32
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018202226 | 2018-10-26 | ||
JP2019075118 | 2019-04-10 | ||
PCT/JP2019/041942 WO2020085493A1 (fr) | 2018-10-26 | 2019-10-25 | Nouveau composé d'indazole ou sel de celui-ci |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3871673A1 true EP3871673A1 (fr) | 2021-09-01 |
EP3871673A4 EP3871673A4 (fr) | 2022-06-22 |
EP3871673B1 EP3871673B1 (fr) | 2024-01-03 |
Family
ID=70331140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19874827.9A Active EP3871673B1 (fr) | 2018-10-26 | 2019-10-25 | Nouveau composé d'indazole ou sel de celui-ci |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210395234A1 (fr) |
EP (1) | EP3871673B1 (fr) |
JP (1) | JP7451419B2 (fr) |
TW (1) | TWI831855B (fr) |
WO (2) | WO2020085504A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021215544A1 (fr) * | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Inhibiteurs de protéine kras g12d |
CN115260103A (zh) * | 2022-09-19 | 2022-11-01 | 苏州美诺医药科技有限公司 | 一种4,5-二卤代-1-(二氟甲基)-1h-咪唑的制备方法 |
US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230181536A1 (en) * | 2020-04-24 | 2023-06-15 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
BR112022022861A2 (pt) * | 2020-05-13 | 2022-12-20 | Basf Se | Compostos, composições agrícolas, semente e métodos para combater ou controlar pragas invertebradas, proteger plantas em crescimento e tratar ou proteger um animal |
EP3909950A1 (fr) * | 2020-05-13 | 2021-11-17 | Basf Se | Composés hétérocycliques destinés à la lutte contre les organismes nuisibles invertébrés |
CN111943879A (zh) * | 2020-08-03 | 2020-11-17 | 南通大学 | 一种(3s,4r)3-氨基-4(甲氧基甲基)吡咯烷-1-甲酸叔丁酯及其合成方法 |
WO2023031781A1 (fr) | 2021-09-01 | 2023-03-09 | Novartis Ag | Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers |
WO2024040131A1 (fr) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Inhibiteurs de pyridopyrimidine kras |
WO2024112654A1 (fr) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Inhibiteurs de kras spirocycliques de dihydropyranopyrimidine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014111559A (ja) * | 2012-07-04 | 2014-06-19 | Nissan Chem Ind Ltd | ピラゾール誘導体および有害生物防除剤 |
WO2014152588A1 (fr) | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Inhibiteurs covalents de k-ras g12c |
CA2926328C (fr) | 2013-10-10 | 2022-11-29 | Araxes Pharma Llc | Quinazoline substituee et derives de quinoline et compositions pharmaceutiques connexes utiles comme inhibiteurs de kras g12c |
AR102094A1 (es) * | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | Inhibidores de proteínas kras con una mutación g12c |
CA3042929A1 (fr) * | 2016-11-08 | 2018-05-17 | Cancer Research Technology Limited | Derives de pyrimidinone en tant qu'inhibiteurs de cdc7 |
JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
CN109670389B (zh) | 2017-10-16 | 2023-04-07 | 富士通株式会社 | 评价人脸图像中的光照条件的方法和设备 |
JP6648797B2 (ja) | 2018-10-04 | 2020-02-14 | 株式会社三洋物産 | 遊技機 |
-
2019
- 2019-10-25 JP JP2020552628A patent/JP7451419B2/ja active Active
- 2019-10-25 WO PCT/JP2019/042005 patent/WO2020085504A1/fr active Application Filing
- 2019-10-25 TW TW108138686A patent/TWI831855B/zh active
- 2019-10-25 US US17/288,780 patent/US20210395234A1/en active Pending
- 2019-10-25 EP EP19874827.9A patent/EP3871673B1/fr active Active
- 2019-10-25 WO PCT/JP2019/041942 patent/WO2020085493A1/fr unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
WO2021215544A1 (fr) * | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Inhibiteurs de protéine kras g12d |
CN115260103A (zh) * | 2022-09-19 | 2022-11-01 | 苏州美诺医药科技有限公司 | 一种4,5-二卤代-1-(二氟甲基)-1h-咪唑的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
TW202029960A (zh) | 2020-08-16 |
JP7451419B2 (ja) | 2024-03-18 |
WO2020085493A1 (fr) | 2020-04-30 |
WO2020085504A1 (fr) | 2020-04-30 |
EP3871673A4 (fr) | 2022-06-22 |
US20210395234A1 (en) | 2021-12-23 |
EP3871673B1 (fr) | 2024-01-03 |
JPWO2020085493A1 (ja) | 2021-09-09 |
TWI831855B (zh) | 2024-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3871673B1 (fr) | Nouveau composé d'indazole ou sel de celui-ci | |
JP6918838B2 (ja) | 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物 | |
EP3268000B1 (fr) | Dérivés de pyrazolo[1,5-a][1,3,5]triazine et de pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de cdk | |
AU2016317521B2 (en) | Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof | |
EP2707359B1 (fr) | Dérivés d'indazole substitués actifs en tant qu'inhibiteurs de kinases | |
ES2426482T3 (es) | Inhibidor de IGF-1R | |
US20230181536A1 (en) | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c | |
AU2017289038A1 (en) | Immunomodulator compounds | |
EP3381896A1 (fr) | Nouveau composé de biphényle ou un sel de celui-ci | |
EP3848367A1 (fr) | Composés tricycliques agissant sur des protéines crbn | |
AU2019382504A1 (en) | Cyclic ureas | |
CN102118969A (zh) | 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂 | |
CN112778284B (zh) | 一种嘧啶并环衍生物及其在医药上的应用 | |
KR101710127B1 (ko) | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 | |
TW202235072A (zh) | 用於治療trpm3介導病症之雜環衍生物 | |
KR20160060034A (ko) | 환상 아민 유도체 및 그 의약 용도 | |
CN116234551A (zh) | 一类1,7-萘啶类化合物及其应用 | |
CA3130245A1 (fr) | Compose heterocyclique, composition pharmaceutique le comprenant, son procede de preparation et son utilisation | |
IL295196A (en) | macrocyclic rip2-kinase inhibitors | |
WO2016072402A1 (fr) | Dérivé d'amine cyclique | |
CN116368131A (zh) | 一类新型Smad3蛋白降解剂及其应用 | |
JPWO2011043381A1 (ja) | ピラゾロチアゾール化合物 | |
KR102384924B1 (ko) | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 | |
EP4328222A1 (fr) | Composé dérivé d'hétéroaryle et son utilisation | |
CN116253724A (zh) | 一类新型Smad3蛋白降解剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210524 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220523 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 417/14 20060101ALI20220517BHEP Ipc: C07D 413/14 20060101ALI20220517BHEP Ipc: C07D 405/14 20060101ALI20220517BHEP Ipc: C07D 403/14 20060101ALI20220517BHEP Ipc: C07D 403/12 20060101ALI20220517BHEP Ipc: C07D 401/14 20060101ALI20220517BHEP Ipc: A61P 43/00 20060101ALI20220517BHEP Ipc: A61P 35/00 20060101ALI20220517BHEP Ipc: A61K 31/496 20060101ALI20220517BHEP Ipc: A61K 31/454 20060101ALI20220517BHEP Ipc: A61K 31/427 20060101ALI20220517BHEP Ipc: A61K 31/422 20060101ALI20220517BHEP Ipc: A61K 31/4178 20060101ALI20220517BHEP Ipc: A61K 31/416 20060101AFI20220517BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230208 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230510 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230714 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019044651 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240103 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20240103 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1646108 Country of ref document: AT Kind code of ref document: T Effective date: 20240103 |